Stockwinners Market Radar for April 28, 2022 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

20:17 EDT FDA approves Bristol-Myers' Camzyos in adults with obstructive HCM - Bristol Myers "announced that the FDA approved Camzyos for the treatment of adults with symptomatic New York Heart Association class II-III obstructive hypertrophic cardiomyopathy, or obstructive HCM, to improve functional capacity and symptoms. Camzyos is the first and only FDA-approved allosteric and reversible inhibitor selective for cardiac myosin that targets the underlying pathophysiology of obstructive HCM. The full U.S. Prescribing Information for Camzyos includes a Boxed WARNING for the risk of heart failure. Camzyos reduces left ventricular ejection fraction (LVEF) and can cause heart failure due to systolic dysfunction. Echocardiogram assessments of LVEF are required prior to and during treatment with Camzyos. Initiation of Camzyos in patients with LVEF less than55% is not recommended. Interrupt Camzyos if LVEF is less than50% at any visit or if the patient experiences heart failure symptoms or worsening clinical status. Concomitant use of Camzyos with certain cytochrome P450 inhibitors or discontinuation of certain cytochrome P450 inducers may increase the risk of heart failure due to systolic dysfunction; therefore, the use of Camzyos is contraindicated with moderate to strong CYP2C19 inhibitors or strong CYP3A4 inhibitors, and moderate to strong CYP2C19 inducers or moderate to strong CYP3A4 inducers. Because of the risk of heart failure due to systolic dysfunction, Camzyos is available only through a restricted program under a Risk Evaluation and Mitigation Strategy called the Camzyos REMS PROGRAM."

19:01 EDT Provident Financial to buy back up to 5% of its common stock - Provident Financial announced that the Company's Board of Directors authorized the repurchase of up to 5% of the Company's common stock, approximately 364,259 shares. The Company will purchase the shares from time to time in the open market or through privately negotiated transactions over a one-year period. The April 2022 stock repurchase plan will become effective on April 28, 2022 and will continue for a period of one year or until completed, whichever occurs first.

18:45 EDT Field Trip Health trading resumes

18:23 EDT Hertz CEO: Our brand is extraordinary - In an interview on CNBC's Mad Money, Stephen Scherr said there is enormous opportunity to remake Hertz. The customer needs to be front and center, he noted. The company is diversifying the customers it approaches, such as renting EV's to ride sharing employees. He's confident that business travel will come back when Covid regulations are relaxed. Demand is outstripping supply that the industry and Hertz have, he added.

18:07 EDT Amazon.com says customer demand 'remains strong' - Seeing continued strength in Prime purchases. Expects approximately $6B of stock based expense in Q2. Says "not immune" to inflationary pressures. Expects fixed cost deleverage to narrow through the year. Expects y/y revenue comps to improve in 2H22. Continuing to see AWS customers make long-term commitments.

17:57 EDT Zymeworks says All Blue Falcons offered $10.50 per share to acquire company - In a 13D/A filing, the company states: "On April 28, 2022, All Blue Falcons delivered to the board of directors of the Issuer a letter outlining a non-binding proposal to acquire the Issuer for $10.50 per Share in cash. The Offer Letter indicates that the Proposal is subject to execution of a definitive transaction agreement and completion of a confirmatory due diligence review of the Issuer by All Blue Falcons. The Offer Letter states that All Blue Falcons seeks an opportunity to discuss the Proposal with the Board and is prepared to enter into an appropriate confidentiality agreement to commence confirmatory due diligence immediately. In connection with the Proposal, All Blue Falcons has entered into discussions with potential co-investors and financing partners that have expressed interest in providing financing for the proposed acquisition. The Reporting Persons may, directly or indirectly, take such additional steps as they may deem appropriate from time to time in connection with the Proposal, including, without limitation, engaging in discussions with other shareholders, potential financing partners or sources of financing and other relevant parties, entering into confidentiality agreements, financing commitments and other agreements, arrangements and understandings in connection with the proposed transaction, and engaging financial, legal and other professional advisors." Shares of Zymeworks are up 34% at $6.64 afterhours.

17:33 EDT Apple says COVID is 'difficult to predict' - Says company had a "great" quarter in Europe, particularly Western Europe. Says Americas revenue above expectations.

17:27 EDT Apple turns lower, down nearly 4% in after-hours amid quarterly call - The downturn comes after the company said it expects Q3 revenue constraints of $4B-$8B.

17:21 EDT Inari Medical to replace TRI Pointe in S&P 400 at open on 5/3

17:19 EDT TRI Pointe to replace US Ecology in S&P 600 at open on 5/3 - Republic Services (RSG) is acquiring US Ecology (ECOL) in a transaction expected to close on or about May 2.

17:16 EDT Apple says iPhone acting install base reached new all-time high - Says monitoring COVID-related supply disruptions. Says company not immune to challenges from supply chain, COVID, and the war in Ukraine. Comments taken from Q2 earnings conference call.

17:01 EDT Parker-Hannifin increases quarterly cash dividend 29% to $1.33 per share - Parker Hannifin announced that its board of directors has declared a regular quarterly cash dividend of $1.33 per share of common stock to shareholders of record as of May 13. The dividend is payable June 3. The dividend represents a 29% increase over the previous quarterly cash dividend of $1.03 per common share and is the company's 288th consecutive quarterly dividend.

17:00 EDT Ignyte Acquisition Corporation trading resumes

16:55 EDT Sysco increases quarterly dividend to 49c per share - Sysco announced that the board of directors has approved a 2c increase in the quarterly cash dividend to 49c per share from the current 47c per share. The new dividend is payable for the first time on July 22 to common stockholders of record at the close of business on July 1.

16:46 EDT Redwood Trust acquires Riverbend Lending, terms not disclosed - Redwood Trust announced that it has entered into a definitive agreement to acquire Riverbend Funding, LLC and its subsidiaries, a private mortgage lender to residential transitional and commercial real estate investors, in an all cash transaction. The addition of Riverbend complements Redwood's existing business purpose mortgage banking platform, CoreVest American Finance Lender, LLC, enhancing CoreVest's suite of products, geographic and production footprint, and client base. Following the close of the acquisition, Riverbend will be integrated into CoreVest. "We are thrilled to announce the acquisition of Riverbend, further demonstrating our commitment to strategically growing our mortgage banking platforms in a manner that benefits our partners," said Chris Abate, Chief Executive Officer of Redwood. "Riverbend's platform adds a complementary product and geographic footprint to CoreVest's existing business. The market for bridge loans continues to be exceptionally strong, supported by increasing sales of newly constructed and rehabilitated homes amidst shrinking housing inventory. This acquisition enhances our scale in this market and we believe that our existing partners will benefit from the products, experience, and strategic lift that Riverbend brings to CoreVest." The acquisition is expected to close in the second quarter of 2022, subject to customary closing conditions.

16:45 EDT Altice USA increases FY22 capex view to $1.7B-$1.8B

16:42 EDT Ecovyst authorizes up to $450M share repurchase program - The Company's Board of Directors has approved a new stock repurchase program authorizing the repurchase of up to $450 million of the Company's outstanding common stock over the next four years. This new program is expected to be funded using cash on hand and cash generated from operations. Ecovyst primarily expects to conduct the repurchase program through negotiated transactions with Ecovyst's equity sponsors, as well as through open market repurchases or other means, including through Rule 10b-18 trading plans or through the use of other techniques such as accelerated share repurchases. The actual timing, number and nature of shares repurchased will depend on a variety of factors, including stock price, trading volume, and general business and market conditions. The repurchase program does not obligate the Company to acquire any number of shares in any specific period or at all and may be amended, suspended or discontinued at any time at the Company's discretion.

16:39 EDT Avery Dennison raises quarterly dividend 10% to 75c per share - Avery Dennison announced that its Board of Directors has increased the company's quarterly dividend. The board declared a quarterly dividend of 75c per share, representing an increase of approximately 10% over the previous dividend rate. The dividend for the second quarter is payable on June 15, 2022 to shareholders of record as of June 1, 2022.

16:38 EDT KKR acquires seven industrial buildings in DFW, Atlanta markets - KKR announced the purchase of seven industrial distribution buildings totaling nearly 1.8 million square feet serving the Dallas Forth Worth and Atlanta markets. The assets were acquired in three separate transactions with different sellers for an aggregate purchase price of approximately $272 million. The purchases were completed over the past two months and include high quality Class A assets in Dallas, Fort Worth and Atlanta - all high growth markets benefitting from strong and diverse tenant demand. The tenant mix across the properties includes a leading ecommerce business, global logistics and manufacturing companies and a national health and beauty retailer. "We are pleased to add these high quality assets to our industrial portfolio," said Ben Brudney, a Director in the Real Estate group at KKR who oversees the firm's industrial investments in the United States. "We continue to see strong demand in fast growing Sunbelt markets, particularly for new, state-of-the-art, Class A product."

16:37 EDT SmartRent names Hiroshi Okamoto CFO - SmartRent announced the appointment of Hiroshi Okamoto as chief financial officer. Joining the Company on May 9, 2022, he will be based at SmartRent's headquarters in Scottsdale, Ariz. "Hiroshi will play an important role in SmartRent's operational excellence," said Lucas Haldeman, CEO of SmartRent. "He brings an impressive track record of leadership in strategy, finance and accounting across early-stage growth companies and established innovators. We look forward to his perspective as we continue to expand our footprint and elevate our brand in the real estate enterprise technology space. I'm thrilled to welcome him to SmartRent's executive team."

16:35 EDT Apple reports Q2 Services revenue $19.82B vs. $16.90B last year

16:35 EDT Apple Q2 wearables, home, accessories revenue $8.81B vs. $7.84B last year

16:34 EDT Apple reports Q2 iPad revenue $7.65B vs. $7.81B last year

16:33 EDT Apple reports Q2 Mac revenue $10.44B vs. $9.10B last year

16:33 EDT Peak Bio, Ignyte Acquisition announce business combination - Peak Bio Co., a clinical-stage biopharmaceutical company focused on developing the next-generation of therapeutics to treat oncology and inflammatory diseases, and Ignyte Acquisition Corp., a special purpose acquisition company, announced they have entered into a definitive business combination agreement. Upon closing of the transaction, Ignyte will be renamed Peak Bio, Inc. and will be led by Hoyoung Huh, MD, Ph.D., Chief Executive Officer of Peak Bio. The Combined Company expects to list its stock on Nasdaq under the ticker symbol "PKBO". A group of healthcare investors including existing Peak Bio stockholders and Palo Alto Investors have committed to participate in the transaction through a $25 million common stock PIPE at a purchase price of $10.00 per share. Gross proceeds of the transaction available to the Combined Company at closing will approximate $82.5 million. Dr. Huh stated that "We are excited about our differentiated inflammation and oncology pipeline and look forward to partnering with Ignyte and advancing our pipeline of potential blockbuster candidates. We believe we will have several near-term catalysts that can be achieved with our cash at closing. Much of our work is the culmination of our efforts at our Korean and US research sites which captured the best of pan pacific financing alternatives, diverse and highly talented scientific acumen, all the while creating a novel mechanism to bring valuable assets to bear into the U.S. NASDAQ market."

16:33 EDT Apple CEO highlights strong customer response to new products - Apple CEO Tim Cook said, "This quarter's record results are a testament to Apple's relentless focus on innovation and our ability to create the best products and services in the world. We are delighted to see the strong customer response to our new products, as well as the progress we're making to become carbon neutral across our supply chain and our products by 2030. We are committed, as ever, to being a force for good in the world - both in what we create and what we leave behind." Its CFO Luca Maestri added, "We are very pleased with our record business results for the March quarter, as we set an all-time revenue record for Services and March quarter revenue records for iPhone, Mac, and Wearables, Home and Accessories. Continued strong customer demand for our products helped us achieve an all-time high for our installed base of active devices. Our strong operating performance generated over $28 billion in operating cash flow, and allowed us to return nearly $27 billion to our shareholders during the quarter."

16:32 EDT Clearwater Paper says resuming previously approved buyback - CEO Arsen Kitch says: "Our first quarter performance represents a strong start to 2022. Inflationary pressures are expected to persist in 2022, which we are offsetting with higher sales prices that were previously announced and operational improvements. Given our strong performance and improved outlook for the year, we are on track to achieve our leverage ratio sooner than anticipated and are resuming our previously approved stock repurchase program."

16:31 EDT Apple boosts quarterly dividend by 5%, buyback by $90B - Apple's board has declared a cash dividend of $23 per share of the company's common stock, an increase of 5%. The dividend is payable on May 12, 2022 to shareholders of record as of the close of business on May 9, 2022. The board also authorized an increase of $90B to the existing share repurchase program.

16:27 EDT Southwestern Energy sees Q2 total production 418-434 Bcfe

16:26 EDT Aldeyra names Bruce Greenberg as interim CFO - Aldeyra Therapeutics "announced that CFO and Treasurer Joshua Reed tendered his resignation to pursue other career opportunities. Mr. Reed will continue to serve as CFO and Treasurer until May 10, 2022 to assist with the transition of his responsibilities and to participate in Aldeyra's upcoming earnings conference call to discuss its financial results for the quarter ended March 31, 2022. Effective as of the Resignation Date, Aldeyra plans to appoint its current Vice President and Controller, Bruce Greenberg, CPA to serve as its Vice President of Finance, Interim CFO, and Treasurer."

16:23 EDT Archaea Energy to acquire NextGen Power Holdings for $215M in cash - Archaea Energy announced that its wholly owned subsidiary, Archaea Infrastructure, LLC, has entered into a definitive purchase and sale agreement with Riverview Investment Holdings LLC, an affiliate of Castleton Commodities International LLC, to purchase NextGen Power Holdings LLC for $215 million in cash, subject to customary adjustments at closing. The transaction is expected to close on or after July 1, 2022. "Today's announcement marks a significant achievement in executing on our strategy of securing as many economically attractive RNG development opportunities as possible, building the biggest and highest quality RNG development backlog in the industry, and growing the long-term earnings power of our business," said Nick Stork, Archaea's Co-Founder and Chief Executive Officer. "The INGENCO platform provides an opportunity set of high-quality projects for our in-house technical and project development professionals to develop and generate compelling returns by building high margin RNG facilities using our Archaea V1 plant design while also exploring opportunities to optimize the existing electricity generation infrastructure."

16:20 EDT SM Energy sees Q2 CapEx $230M-$250M - In the second quarter 2022, the company expects to drill 27 net wells, of which 12 are planned for South Texas and 15 are planned for the Midland Basin, and turn-in-line 20 net wells, of which 12 are planned for South Texas and 8 are planned for the Midland Basin. Production: 13.0-13.3 MMBoe, or 143-146 MBoe/d, at approximately 45% oil and 60% liquids. The expected slight decline in sequential production reflects the lower number of new flowing completions in the fall of 2021 and first quarter 2022.

16:18 EDT Arthur J. Gallagher suspended relationships with clients based in Russia - Gallagher does not have any offices or direct operations within Ukraine or Russia. The company said: "While we had a small number of clients that were based in or had operations within Russia, we have suspended those relationships and are no longer providing services to these clients. We have also implemented robust procedures designed to ensure that we are in compliance with all applicable sanctions laws. We currently estimate these actions will adversely impact full year 2022 brokerage segment annual revenues by up to $10 million and full year 2022 net after tax earnings by up to $0.03 per share, with a $0.01 adverse impact in first quarter of 2022. The indirect impact of the ongoing conflict is difficult to estimate, but we currently believe it will not be significant to our full year 2022 financial results."

16:16 EDT Incyte announce strategic alliance for Ruxolitinib Cream in Japan - Incyte "announced that the companies have entered into a Strategic Alliance Agreement for the development, manufacturing and exclusive commercialization of ruxolitinib cream, a novel cream formulation of Incyte's selective JAK2 inhibitor ruxolitinib, for treatment of autoimmune and inflammatory dermatology indications in Japan. Under the terms of the agreement, Maruho will make an upfront payment to Incyte and Incyte is eligible to receive additional potential development, regulatory and commercial milestones and royalties on net sales of the licensed product in Japan. Maruho will receive the rights to develop, manufacture and exclusively commercialize ruxolitinib cream, and other potential future topical formulations of ruxolitinib, in autoimmune and inflammatory dermatologic diseases, including vitiligo and atopic dermatitis, in Japan."

16:11 EDT Fortune Brands announces intent to separate into two separate companies

16:09 EDT Amazon reports Q1 AWS net sales $18.44B vs. $13.5B a year ago - Amazon reports Q1 AWS operating income of $6.52B vs. $4.16B a year ago.

16:01 EDT Intel CEO: Q1 was a strong start to the year, exceeded expectations - "Q1 was a strong start to the year, exceeding expectations on both the top- and bottom-line," said Pat Gelsinger, Intel CEO. "With a $1 trillion market opportunity ahead of us, we remain laser focused on our IDM 2.0 strategy. We executed well against that strategy in Q1, delivering key product and technology milestones and announcing plans to expand our manufacturing capacity in both the US and Europe to meet the continued demand for semiconductors and drive a more balanced, resilient global supply chain."

16:00 EDT Ignyte Acquisition Corporation trading halted, news pending

15:58 EDT Linde rises after Q1 results prompt FY22 guidance hike - Shares of Linde plc are up 3% to $315.21 in late day trading after the company reported earlier that Q1 diluted EPS of $2.30 were up 24% compared to the prior year. Excluding Linde AG purchase accounting impacts and other charges, adjusted EPS of $2.93, were 18% above prior year and 6% higher sequentially. Linde's sales for the first quarter of $8.21B were 13% above prior year. Compared to prior year, underlying sales increased 9%, including 6% price attainment and 3% higher volumes, mostly from the manufacturing, chemicals and energy end markets. Sequentially, underlying sales grew 2%, driven by 3% higher pricing partially offset by seasonally lower volumes. Linde CEO Sanjiv Lamba said, "Linde employees delivered another strong quarter of quality financial results with ROC reaching a new record of 18.9% and operating margins expanding 130 basis points excluding cost-pass through. In addition, EPS grew 18% to an all-time high of $2.93. The business model continues to deliver in any environment, demonstrating resiliency during economic downturns and significant growth during the recovery. Looking ahead, the geopolitical and macro environment has become more uncertain, but I have confidence the company will continue to deliver on commitments to shareholders." For the second quarter of 2022, Linde expects adjusted diluted EPS in the range of $2.90-$3.00, up 7% to 11% versus prior-year quarter. This guidance assumes flat currency sequentially and a headwind of 3% year-over-year. For the full year 2022, the company expects adjusted diluted EPS to be in the range of $11.65-$11.90, up 9% to 11% versus prior year or 11% to 13% excluding currency headwind. This guidance range excludes contribution from Russian earnings by the second half of 2022 as the company continues to scale back Russian operations and wind down engineering projects affected by sanctions. Full-year capital expenditures are expected to be in the range of $3B-$3.4B to support maintenance and growth requirements including the $3.5B contractual sale of gas project backlog, the company stated.

15:16 EDT Biolase announces 1-for-25 reverse stock split - Biolase announced that it held its annual meeting of stockholders on April 28 where the company's stockholders granted the Board of Directors the discretion to effect a reverse stock split of the company's common stock at a ratio between 1-to-2 and 1-to-25. Shortly following the annual meeting, the Board of Directors exercised such discretion to effect a 1-for-25 reverse stock split that will become effective at 11:59 p.m. Eastern Time on April 28, and the company's common stock will begin trading on a split-adjusted basis at the opening of the market on April 29.

14:00 EDT InMed has no affiliation with marijuana, CEO Eric Adams tells The Fly

14:00 EDT IntegraSyn development 'coming along quite well,' InMed CEO says

13:46 EDT Blizzard to reveal new mobile 'Warcraft' title May 3 - Blizzard, a division of Activision Blizzard (ATVI), announced an event on May 3 at 10:00 am PT where it will reveal a new mobile game set in the "Warcraft" universe. The Fly notes that Activision Blizzard shareholders approved the game maker's takeover by Microsoft (MSFT). Reference Link

13:33 EDT Prescience reports 6.7% stake in MiMedx, sees 'chronic undervaluation' - Prescience Investment Group disclosed a 6.7% stake in MiMedx, which represents over 7.6M shares. Prescience said it believes the sires, when acquired, were undervalued and represented an attractive investment opportunity. It said that as one of the largest and longest-tenured shareholders, it has "been closely monitoring developments at the Issuer and are deeply concerned by the Issuer's operational performance, strategic direction, and stock price performance." Prescience believes MiMedx has "failed to accurately and effectively communicate the value of its wound care business and pipeline to the investment community, resulting in the chronic undervaluation" of its equity. Prescience is "especially concerned by the Issuer's failure to properly convey the immense potential and promise of Amniofix to the investment community." The fund says Amniofix "has a high chance of regulatory success and that the product's peak sales could exceed $15 billion. Yet, at the moment, the market is assigning little-to-no value to this product in the Issuer's share price." Prescience has engaged in discussions with the board, and are continuing to engage in such discussions, "regarding suggestions aimed at improving the governance and chronic underperformance of the Issuer, including the addition of shareholder representatives to the Board."

12:41 EDT Southwest sees H2 CASM-ex growth rate up sequentially from H1 - Says it previously intended to add 8,000 workers this year.

12:37 EDT Southwest sees 'healthy' profit for Q2 - Says still doesn't expect network to be fully optimized until next year. Says will add 10,000 staff net of attrition this year. Says experienced "surge" in demand and bookings in March. Comments taken from Q1 earnings conference call.

12:31 EDT AGCO board declares special dividend of $4.50 per share - AGCO announced that its Board of Directors declared a variable special dividend in the amount of $4.50 per share, payable on June 21, 2022 to shareholders of record at the close of business on May 20, 2022.

12:22 EDT NBA says Celtics-Nets averaged 4.8M viewers across ABC, ESPN, and TNT - According to the National Basketball Association, the four-game series between the Boston Celtics and Brooklyn Nets averaged 4.8M viewers across ABC (DIS), ESPN and TNT (WBD), making it the most-viewed first-round NBA playoff series since Warriors vs. Rockets in 2016 and most-viewed Eastern Conference first-round series since Heat vs. Knicks in 2012. Reference Link

12:05 EDT Turkcell trading resumes

12:00 EDT Unisys falls -16.8% - Unisys is down -16.8%, or -$2.85 to $14.16.

12:00 EDT Teladoc falls -48.2% - Teladoc is down -48.2%, or -$26.98 to $29.01.

12:00 EDT Ocwen rises 19.3% - Ocwen is up 19.3%, or $3.48 to $21.47.

11:49 EDT Vale denies allegations of SEC, will defend itself 'vigorously' - Vale S.A confirms that the Securities and Exchange Commission of the United States initiated legal action against the company in the District Court for the Eastern District of New York, United States, alleging that certain disclosures of Vale would violate the securities laws of the United States related to the security management of barragens da Vale before the tragic rupture of Barragem in Brumadinho, Minas Gerais, Brazil, in January 2019. Vale denies the allegations of the SEC, including the allegation that its disclosures violated the law of the United States, and will defend itself "vigorously," the company stated. Reference Link

11:42 EDT Meihua International Medical Tech Co Ltd trading resumes

11:37 EDT Twitter admits it overstated user numbers between 2019-2021 - Earlier, Twitter revealed what it described as an "error" introduced in the first quarter of 2019 that "resulted in an overstatement of mDAU" that went undiscovered through 2021. The difference between the figures Twitter reported over the past year and the true count ranged between 1.4M-1.9M it said, or just below 1% of the total. Twitter specifically stated: "In March of 2019, we launched a feature that allowed people to link multiple separate accounts together in order to conveniently switch between accounts. An error was made at that time, such that actions taken via the primary account resulted in all linked accounts being counted as mDAU. This resulted in an overstatement of mDAU from Q1'19 through Q4'21."

11:32 EDT Microsoft says Xbox & Bethesda Games Showcase to stream June 12 - Microsoft said that the Xbox & Bethesda Games Showcase will stream on Sunday, June 12 at 10 a.m. PT. This show will feature titles coming from Xbox Game Studios, Bethesda, and Microsoft's partners around the world, the company said. Reference Link

11:09 EDT WVS Financial Corp trading resumes

11:01 EDT ADM names John Stott as president for ADM Investor Services - ADM announced that John Stott will serve as the new president for ADM Investor Services, effective July 1. He replaces Tom Kadlec, who announced his retirement after nearly 32 years with ADM. Stott is currently Group Vice President, Finance, Corporate Treasurer, and CFO of Global Technology and 1ADM.

10:33 EDT Gracell to present longer-term follow-up clinical data evaluating GC012F at ASCO - Gracell Biotechnologies announced the details of its oral abstract presentation at the 2022 American Society of Clinical Oncology, or ASCO, Annual Meeting, being held from June 3-7. Longer-term follow-up clinical data from a multicenter investigator-initiated trial evaluating GC012F for the treatment of relapsed/refractory multiple myeloma will be presented at an oral abstract session. GC012F is an autologous CAR-T therapeutic candidate dual-targeting B cell maturation antigen and CD19. In November 2021, GC012F was granted Orphan Drug Designation for the treatment of multiple myeloma by the U.S. Food and Drug Administration, the company noted.

10:02 EDT GE Healthcare, Medtronic collaborate for outpatient care - GE Healthcare (GE) and Medtronic (MDT) announce a collaboration focused on the unique needs and demand for care at Ambulatory Surgery Centers and Office Based Labs. Under this new collaboration, customers can access extensive product portfolios, financial solutions, and exceptional service. The COVID-19 pandemic accelerated the movement of procedures into the outpatient environment while also driving disease rates higher, resulting in procedure growth in facilities outside traditional hospitals, and this growth trend is expected to continue for years to come. Also, since CMS approved payments for certain cardiovascular procedures in 2020, fixed c-arm imaging systems have been used more and more frequently in ASCs and OBLs for cardiac and peripheral vascular procedures. While patient needs are increasing, there remain high costs and complexity associated with expanding an existing ASC or building a new one. GE Healthcare and Medtronic seek to help ASCs navigate these challenges, bringing the best of each company to deliver high-quality and cost-effective advanced technology, financial solutions, and personal service. For GE Healthcare, this includes consultative planning, construction, a comprehensive suite of equipment, and exceptional service and digital solutions, including the Edison-powered AutoRight A.I.-based interventional imaging chain, which can help clinicians provide the right image at the right dose automatically for each patient. For Medtronic, this means providing an extensive portfolio of products for a diverse range of service lines in the ASC and OBL, from cardiac rhythm to pain management, peripheral vascular to kyphoplasty. In addition to products, Medtronic will continue to offer the service that customers have come to expect from their field experts as well as reimbursement support, remote solutions, and more. From staff workflow to patient care and more, GE Healthcare and Medtronic experts and solutions help outpatient health center owners and clinicians achieve their vision.

10:01 EDT Swvl Holdings Corp trading resumes

10:00 EDT Studio City falls -22.8% - Studio City is down -22.8%, or -$1.24 to $4.21.

10:00 EDT Pitney Bowes rises 19.8% - Pitney Bowes is up 19.8%, or 85c to $5.16.

10:00 EDT SQZ Biotechnologies rises 24.5% - SQZ Biotechnologies is up 24.5%, or 68c to $3.45.

09:55 EDT Teladoc trading resumes

09:50 EDT Teladoc trading halted, volatility trading pause

09:47 EDT Peabody Energy falls -12.8% - Peabody Energy is down -12.8%, or -$3.40 to $23.10.

09:47 EDT Teladoc falls -46.4% - Teladoc is down -46.4%, or -$26.00 to $29.99.

09:47 EDT SQZ Biotechnologies rises 12.6% - SQZ Biotechnologies is up 12.6%, or 35c to $3.12.

09:46 EDT Peabody Energy slides following weaker quarterly results - Shares of Peabody Energy Corp. (BTU) are under pressure on Thursday morning after the coal producer reported adjusted EBITDA and first quarter revenue that missed consensus estimates. Peabody posted a net loss of $119.5 million for the first quarter, 49% bigger than the loss reported at the same time last year. The worst quarterly loss since 2020 comes as the booming coal market triggered a $301M charge for the company's hedging operations. On a per-share basis, the mining giant said it had a loss of 88c in the first quarter, versus expectations for $2.13 of earnings. Earnings, adjusted for non-recurring costs and to extinguish debt, came to $1.51 per share. The coal mining company posted first quarter revenue of $691.4M, with consensus at $1.11B. In Thursday morning trading, shares of Peabody Energy have dropped over 18% to $21.68.

09:40 EDT Studio City International Holdings Limited (Class A ADS) trading resumes

09:38 EDT TNON Stock trading resumes

09:36 EDT Victor Oladipo renews brand ambassador agreement with EzFill - EzFill Holdings announced Miami Heat star Victor Oladipo will promote the Company to his fans and supporters as Brand Ambassador. The NBA veteran, who is an investor and longtime EzFill customer, will share the convenience, safety, and touch-free benefits of the fast growing on-demand fueling service with his many fans, supporters, and social media followers in Florida and around the world. Oladipo has renewed his agreement to serve as Brand Ambassador to EzFill, which plans to rapidly expand its residential offering through strategic relationships with Brand Ambassadors in markets throughout the state of Florida including Miami, West Palm Beach, Orlando, and Tampa.

09:35 EDT Studio City International Holdings Limited (Class A ADS) trading halted, volatility trading pause

09:34 EDT Accuray CEO Levine to retire, Winter to succeed, appoints Pervaiz as CFO - Accuray announced that Suzanne Winter, President, will succeed Joshua Levine as the company's Chief Executive Officer, CEO, effective July 1, 2022. Levine will retire from the Accuray Board of Directors at the end of the company's fiscal year on June 30, 2022 and will remain available to the company in a consulting role through June 30, 2023 to ensure a smooth transition over the next year. Winter has been appointed as a director of the company and will join the Board effective April 27, 2022. Winter joined Accuray as Senior Vice President, Chief Commercial Officer in October 2019 and has served as the company's President since July 2021. Accuray also announced that Ali Pervaiz has been appointed Senior Vice President and Chief Financial Officer, CFO, effective May 9, 2022. Pervaiz has been with Accuray for two years and currently serves as the company's Vice President, Global Commercial Operations.

09:34 EDT 22nd Century CEO expects 2022 to be 'truly transformational' - 22nd Century Group announced that the Company has issued its annual letter to shareholders as part of 22nd Century's 2021 Annual Report. The letter read in part, " "Helps You Smoke Less." These four words from the U.S. Food and Drug Administration on December 23rd, 2021, capped off an amazing year at 22nd Century Group and ushered in what may be the most disruptive new tobacco product of our generation - our VLN reduced nicotine content combustible cigarettes. VLN is designed specifically to help smokers smoke fewer cigarettes. In doing so, we can fulfill our primary mission to reduce the harm associated with smoking. Our VLN authorization reflects years of scientific research, federally funded clinical studies and regulatory persistence to secure the first and only Modified Risk Tobacco Product authorization granted to a combustible cigarette. It also signifies a new starting line as we bring VLN to the $800 billion global tobacco market - 85% of which is focused on combustible tobacco cigarettes. With more than 34 million smokers in the U.S. and more than a billion smokers around the world, this tremendous global market is ripe for disruption. In the U.S., we know that more than three out of four adult smokers want to quit and 50% attempt to quit each year. Yet less than 10% of smokers are able to successfully quit. More and more, smokers are actively seeking alternatives to addictive, conventional cigarettes, most of which are other addictive nicotine delivery systems. We offer adult smokers something different - a way to reduce their smoking; a way to reduce their nicotine consumption. We are encouraged by data from our own consumer perception studies showing that 60% of current adult smokers are likely to use VLN, and from extensive federally funded studies showing that reduced nicotine cigarettes like VLN are effective in helping smokers truly smoke less...As we look to the year ahead, we expect 2022 will be truly transformational as we complete our VLN pilot in Chicago and move to full, nationwide market launch. We have expanded our planned hemp crop at Needle Rock Farms for 2022 and look forward to exciting developments in hops as we scale up our efforts in that franchise. In closing, I thank you for your continued support of 22nd Century and its initiatives and look forward to our continued progress in these exciting markets."

09:32 EDT OST Stock trading halted, volatility trading pause

09:30 EDT Remitly expand relationship with Visa with real-time push payments Visa Direct - Remitly Global (RELY) announced the expansion of its relationship with Visa by making available Visa (V) Direct, Visa's real-time push payments platform, to its customers in Canada.[1] Remitly customers in Canada will be able to send funds to eligible recipients in countries around the world with a broader array of payout options that will now include Visa cards, in addition to the pre-existing bank account, digital wallet, and cash payout options. "At Remitly, we say that remittances are global, but customers are local," said Matt Oppenheimer, CEO, Remitly. "To provide best-in-class financial services to our customers, we offer localized experiences at scale - meaning offering locally relevant, convenient, and trusted options to send money. We are proud to add Visa Direct as an additional option for our customers in Canada, as we continue to move toward our vision of becoming the most trusted financial services provider for immigrants and their families." Visa Direct enables Remitly to provide its US and Canadian customers with the ability to send money internationally directly to bank accounts by simply providing their recipient's name and 16-digit Visa debit card number. Since March 2020, Remitly has expanded its partnership with Visa, and customers can now send from 16 countries and receive digital money transfers to bank accounts in more than 65 countries.

09:30 EDT WVS Financial Corp trading halted, volatility trading pause

09:27 EDT American Express enters integration collaboration with Billtrust - American Express (AXP) announced a collaboration with Billtrust (BTRS) to enable suppliers to streamline acceptance of American Express virtual cards. With this integration, suppliers will have the ability to automate and accelerate virtual card payments from customers while receiving a real-time view of their outstanding invoices and current cash flow.

09:25 EDT MasterCard sees FY22 net revenue up at high end of high teens rate

09:22 EDT Creative Realities renews 3-year digital software contract with large retailer - Creative Realities announced that one if its long standing retail customers agreed to a three-year term for the company to continue delivering software as a service to its vast fleet of store locations throughout the US. The ReflectView software connects with digital displays to help differentiate key strategic zones to take the guess work out of shopping.

09:21 EDT SEC charges Vale with misleading investors about safety ahead of dam collapse - The Securities and Exchange Commission charged Vale S.A., a publicly traded Brazilian mining company and one of the world's largest iron ore producers, with making false and misleading claims about the safety of its dams prior to the January 2019 collapse of its Brumadinho dam. The collapse killed 270 people, caused immeasurable environmental and social harm, and led to a loss of more than $4B in Vale's market capitalization. According to the SEC's complaint, beginning in 2016, Vale manipulated multiple dam safety audits; obtained numerous fraudulent stability certificates; and regularly misled local governments, communities, and investors about the safety of the Brumadinho dam through its environmental, social, and governance disclosures. The SEC's complaint also alleges that, for years, Vale knew that the Brumadinho dam, which was built to contain potentially toxic byproducts from mining operations, did not meet internationally-recognized standards for dam safety. The SEC's complaint, filed in U.S. District Court for the Eastern District of New York, charges Vale with violating antifraud and reporting provisions of the federal securities laws and seeks injunctive relief, disgorgement plus prejudgment interest, and civil penalties. Reference Link

09:20 EDT Rivian Automotive, Clearloop partner on renewable electricity - Rivian and Nashville-based Clearloop are partnering to bring online Rivian's first megawatt of renewable electricity. Their approach brings solar energy to a part of the country where new renewable development can help to maximize system-wide carbon reductions. The Paris Solar Farm - Puryear in Tennessee will be the first installation in Henry County, which is located on the Sun Belt roughly 100 miles east of Nashville. The project utilizes unique approaches to financing and siting that aim to put renewables on more fossil-fueled grids where they can displace more coal and natural gas.

09:19 EDT First Financial Northwest reports Q1 EPS 36c, consensus 27c - The Company's book value per share increased to $17.32 at March 31, 2022, compared to $17.30 at December 31, 2021, and $16.35 at March 31, 2021. The Bank's Tier 1 leverage and total capital ratios at March 31, 2022, were 10.5% and 15.3%, respectively, compared to 10.3% and 15.5%, respectively, at December 31, 2021, and 10.2% and 15.6%, respectively at March 31, 2021. "The first quarter of 2022 showed continued improvement in our funding base, with our average cost of funds declining to 0.51% from 0.55% in the quarter ended December 31, 2021, and 0.91% in the quarter ended March 31, 2021," stated Joseph Kiley, III, President and CEO. "We anticipate that this improvement will continue since we have approximately $142.0 million in retail certificates of deposit at a weighted average rate of 1.0% maturing in the next 12 months, and an additional $91.4 million maturing in the subsequent 12 to 24 months, at a weighted average rate of 1.61%. The favorable impact of repricing maturing certificates of deposit on our average cost of funds may be less significant than we currently anticipate depending on the extent our competition for rate sensitive deposits responds to the Federal Reserve increasing the target federal funds rate," continued Kiley. "In addition to the ongoing improvement in our cost of funds, I was pleased to see checking account deposit balances increase $14.7 million during the quarter. We also saw continued loan growth despite $5.7 million in Paycheck Protection Program loan repayments and forgiveness, with net loans receivable increasing $17.9 million to $1.12 billion during the quarter, led by growth in one-to-four family residential and multifamily loans," continued Kiley. "As a result of our quarterly analysis of our loan portfolio, we downgraded to substandard $6.4 million of participation loans secured by medical rehabilitation facilities that were previously downgraded to special mention in the quarter ended June 30, 2021, due to the unavailability of elective medical procedures during the pandemic. In addition, we further downgraded a $1.7 million multifamily property loan to substandard subsequent to an overall financial analysis of a single borrowing relationship with multiple loans. These substandard loans were analyzed for impairment and the analysis concluded that no losses are anticipated from these loans, resulting in a recapture of provision for loan losses of the amount previously allocated to these loans. We also downgraded a $6.3 million loan where we are a participating lender on a nursing home facility to special mention as its recovery is occurring slower than anticipated as additional occupants are moving into such facilities at a slower pace compared to activity prior to the pandemic. Changes in the mix of our loan portfolio also impacted the allowance for loan and lease losses, with growth in the lower risk one-to-four family residential and reduced balances in other business loans that carry higher loan loss reserves impacting the analysis. In addition, $20.7 million in loans converted from construction loans to permanent multifamily loans, further contributing to the $500,000 recapture of provision for loan losses during the quarter, compared to a provision for loan losses of $600,000 in the quarter ended December 31, 2021," concluded Kiley.

09:17 EDT Matterport announces it is expanding its presence in Japan - Matterport announced it is expanding its presence in Japan. As part of the expansion, Matterport will increase investments to open new sales channels and broaden its customer service operations to support the growing adoption of the Matterport digital twin platform within the country. "Use of Matterport first spread by word-of-mouth, and before we knew it, a community of users had formed naturally within the company," said Yasutomo Matsuoka, Chief Researcher, Advanced Mathematical Sciences & Informatics Group, Future & Advanced Technology Research Department, Research & Development Institute at Takenaka Corporation. "I think it's simple-good things become popular. Matterport's digital twin technology not only provides the high-quality, precise data required to meet the needs of those working in the field, but also enables remote checking by personnel located overseas, leading to significant reductions in travel and labor costs."

09:16 EDT ENGlobal awarded SCADA system contract for public school district - ENG announced that its wholly owned subsidiary, ENGlobal Government Services, has been awarded a contract to implement a Supervisory Control And Data Acquisition system for a large midwestern public school district. The contract, whose value is expected to exceed $1 million, includes upgrading or replacing the district's current security and fire systems and implementing a SCADA system designed by EGS that will provide for centralized monitoring from a centralized location of these systems alarm alerts for approximately 100 school and administration sites within the district.

09:14 EDT 180 Degree receives $12.3M from buyout of potential future milestones of Petra - 180 Degree Capital (TURN) announced that it sold its rights to potential future milestone payments received from the acquisition of Petra Pharma Corporation by Eli Lilly and Company (LLY) for $12.3M in cash, or $1.19 per share. These potential future milestone payments were fair valued at $7.6M as of December 31, 2021. "We are excited to announce the monetization of another private investment in 2022," said Kevin Rendino, Chief Executive Officer of 180. "Not every monetization is of the same magnitude, but this one is extremely meaningful to 180. We have continuously said that 180 is in a fortunate position to be able to sell its private portfolio holdings when it makes sense to do so, rather than having to sell in order to survive. This sale embodies how our strong financial position allowed us to take advantage of an opportunity to sell our milestone payments at a significant premium to their value as of the end of 2021. With this sale, the acquisition of TARA Biosystems, Inc. by Valo Health, LLC, and the announcement of the intent of D-Wave Systems, Inc. to merge with the SPAC, DPCM Capital, Inc., we have made considerable progress in 2022 to reorient our assets to public and public-related securities. 180's remaining private portfolio has only one material position, AgBiome, LLC, and with these monetizations, approximately 83% of our pro forma cash and investment assets would be in cash and public and public-related securities.1 We continue to make progress towards our goal of 180 of having all of its assets in cash and public and public-related securities. We believe this progress should enable us to narrow the discount that our stock trades to our NAV."

09:12 EDT Clarus announces notice of allowance from USPTO for patent covering JATENZO - Clarus Therapeutics announced that it has received a notice of allowance from the United States Patent and Trademark Office, USPTO for claims that cover its oral testosterone replacement product, JATENZO. Patent application No. 16/656,178 entitled "Pharmaceutical Delivery Systems for Hydrophobic Drugs and Compositions Comprising Same" covers Clarus' commercialized product, JATENZO. The U.S. patent scheduled to issue from this application will expire in 2026. "As we continue to grow the JATENZO brand, we are extremely pleased that we can further reinforce its robust intellectual property portfolio," said Dr. Robert Dudley, President and Chief Executive Officer of Clarus. "Once issued, this new patent will be listed in FDA's Orange Book, thus bringing the total number of patents covering JATENZO in the United States to eight."

09:11 EDT Twilio announces Reeny Sondhi as CDO, Amy Holcroft as CPO - Twilio announced two new hires. Reeny Sondhi joined the company as chief digital officer, and Amy Holcroft joined the company as chief privacy officer. Both roles are new to Twilio, as businesses increasingly look to digital channels to drive customer engagement, making digital privacy and rights a top priority for Twilio and its customers across all industries and regions. As chief digital officer, Sondhi will lead the scale of all technology operations needed as the company focuses on scaling and becoming an end-to-end customer engagement platform. She is based in San Francisco and will report to COO, Khozema Shipchandler. As chief privacy officer, Holcroft will lead the team responsible for protecting the interests of Twilio's more than 250,000 customers and enabling their compliance with information privacy laws. Holcroft is based in London and will report to Twilio's chief legal officer, Dana Wagner.

09:10 EDT Abbott's Amplatzer delivery sheath available in the U.S. - Abbott announced U.S. availability of its Amplatzer Steerable Delivery Sheath, which is used with the company's Amplatzer Amulet Left Atrial Appendage Occluder to treat people with atrial fibrillation who are at risk of ischemic stroke. The LAA is a small pouch connected to the upper left chamber of the heart. For patients with AFib who are unable to take blood-thinning medication long term, physicians may opt for a minimally invasive procedure using devices like Abbott's Amulet to seal off the LAA entirely and reduce the risk of stroke. Abbott's Amplatzer Steerable Delivery Sheath is approved in Europe and Canada and cleared for use in the U.S. Receiving initial CE Mark approval in 2013, the Amplatzer Amulet LAA Occluder has been approved for use in more than 80 countries.

09:10 EDT Muscle Maker's Pokemoto enters into Philadelphia market - Muscle Maker announced that its Pokemoto Division is expanding into the Northeast Philadelphia market. This will represent the first Pokemoto location in Pennsylvania while also acting as a seed location to further franchise sales efforts in Philadelphia. "After seeing the initial results in the Fort Meade Muscle Maker Grill conversion to Pokemoto, we're excited to open Pokemoto in the former Muscle Maker Grill location in Philadelphia," said Michael Roper, CEO of Pokemoto and Muscle Maker Grill. "It's a great location and this opening will put a new market on the map for the brand. We're looking closely at corporate Muscle Maker Grill locations to determine if we'll convert to Pokemoto or add Pokemoto in some capacity to optimize our real estate. We're exploring all opportunities at this point and the Fort Meade results have us exploring outside of the box. The ultimate goal is to increase topline sales while continuing on our mission of serving up "healthier for you" options to our valued guests. We'll continue to provide updates on the optimization strategy and results as we progress down this path."

09:09 EDT Microchip announces release of five new product families - Microchip Technology announces the release of five new product families and over 60 new individual devices that offer embedded designers simple solutions to their most common problems. Designers who are looking to create innovative designs are turning to Microchip's new product families of PIC and AVR MCUs because of their processing power, ability to easily communicate with other chips, and analog peripherals that have been built to be exceptionally configurable without having to make changes to the Printed Circuit Board. These devices combine ASIC-like capabilities with a simple development experience that extends traditional MCU capabilities and allows them to be configured as smart peripheral chips. Smart peripherals, like the software-controlled op amp found on the PIC16F171 family, the Multi-Voltage I/O and Analog-to-Digital Converter with Computation add value to applications that otherwise would not use traditional MCUs.

09:07 EDT Tetra Tech awarded patent for Volans software - Tetra Tech announced that it was awarded U.S. Patent Number 11,269,957 for its proprietary Volans 3D animation and visualization software. Volans(TM) saves the aviation industry significant time and money in meeting their sustainability goals of building a net zero sustainable aviation system. Volans is used for environmental analysis and visualization by the Federal Aviation Administration and air navigation organizations in Canada, Australia, South America, and Europe; and local airport authorities.

09:07 EDT Suncor up 8% after Elliott calls for strategic and management review - Suncor shares are up $2.62, or 8%, to $35.50 in pre-market trading in New York.

09:06 EDT MasterCard CEO: U.S. retail spending remains 'healthy'

09:06 EDT MasterCard CEO: Consumer spending remains strong

09:06 EDT XBiotech announces ANSM approval, INSA funding for trials of Natrunix - XBiotech announced that the French National Agency, ANSM, for the Safety of Medicines and Health Products approved the launch of a multicenter randomized clinical study for XBiotech's candidate cancer treatment Natrunix in combination with trifluridine/tipiracil for the treatment of colorectal cancer. The French National Cancer Institute, INCA, has also awarded a grant to fund all clinical costs for the study. Investigators will combine Natrunix and trifluridine/tipiracil as a new candidate therapy for metastatic colorectal cancer in subjects that have failed earlier treatment with oxaliplatin, irinotecan, and fluoropyrimidine. The study will randomize patients to receive the Natrunix plus chemotherapy or placebo plus chemotherapy and is designed to seamlessly proceed to a Phase III study based on achievement of certain early efficacy milestones. The first portion of the study will be an open label, dose escalation. The Phase II portion will be a multicenter, randomized, double blind, placebo-controlled, non-comparative trial that will enroll 160 subjects. The main objective of the phase II study is to evaluate the efficacy of Natrunix + trifluridine/tipiracil in comparison with placebo + trifluridine/tipiracil with respect to 6-month overall survival in patients with refractory metastatic colorectal cancer. Secondary efficacy measures in the phase 2 portion will include progression free survival, median overall survival, tolerance, quality of life, serum markers of inflammatory cytokines, and tumor markers by immunohistochemistry. With successful completion of the primary endpoint in the Phase II portion, the study will continue into a phase III trial with the number of additional patients enrolled based upon results from the Phase II.

09:05 EDT Northrop Grumman provides 2022 sector guidance - For 2022 sees: Aeronautics Systems sales mid to high $10B, OM rate ~10%; Defense Systems sales mid to high $5B, OM rate high 11%; Missions Systems sales mid $10B, OM rate low 15%; Space Systems sales mid to high $11B, OM rate low 10%; Eliminations low ($2B), OM rate mid to high 12%. Prior 2022 view: Aeronautics Systems sales mid to high $10B, OM rate ~10%; Defense Systems sales high $5B, OM rate high 11%; Missions Systems sales mid $10B, OM rate low 15%; Space Systems sales mid $11B, OM rate low 10%; Eliminations ($2.1B), OM rate mid to high 12%. Guidance taken from investor presentation slides for Q1.

09:04 EDT Curator Hotel and Resort selects Canary Technologies as preferred vendor - Canary Technologies announced that it has been selected as a preferred vendor by Curator Hotel & Resort Collection, founded by Pebblebrook Hotel Trust, for its Digital Authorizations solution. Under the agreement, Canary will provide digital credit card authorizations to support Curator's collection of independent lifestyle hotels and resorts. With Canary's Digital Authorizations solution, Curator's member properties will be able to send each guest a unique link so they can enter their credit card information through a PCI-compliant and secure online form, instead of having to fill out paper forms in person upon check-in. Hotels will also have access to Canary's web dashboard to keep track of each guest's digital authorization online. Canary's Digital Authorizations is fully compliant with Payment Card Industry standards that all businesses must adhere to if they capture, process, transmit, or store credit or debit card information. "Canary's Digital Authorizations was an obvious choice considering its ease of implementation, user-friendly interface and track record of reducing chargebacks, and we are excited to be able to leverage the benefits of this impactful technology for our members," said Curator Vice President Austin Segal.

09:03 EDT Elliott sends letter to Suncor, sees $30B value creation opportunity

09:02 EDT Elliott calls for strategic and management review at Suncor

08:59 EDT Expion360 begins shipments of over 500 e360 lithium batteries - Expion360 has begun shipping its lithium-ion batteries and accessories to AIM Wholesale. Expion360 shipped an initial 192 units in March and is scheduled to ship an additional 320 units over the next six months. The orders are being driven in part by demand from AIM's customers for Expion360's 120 amp hours lithium-ion batteries. Expion360 products will be distributed through AIM's Phoenix, Arizona headquarters and regional distribution centers in California, Texas and Utah.

08:57 EDT Caterpillar says does not expect a benefit from dealer restocking in 2022 - Says manufacturing costs remain elevated but "within expectations." Says credit portfolio remains "high quality." Expects to achieve FY free cash flow target.

08:56 EDT Edesa Biotech announces EB01 patient recruitment ahead of schedule - Edesa Biotech announced that patient recruitment for a Phase 2b clinical study evaluating the company's drug candidate, designated EB01, as a monotherapy for chronic allergic contact dermatitis, or ACD, has been enrolling ahead of schedule. Based on the current pace of recruitment, which had previously been impacted by pandemic-related shutdowns, the company anticipates completing enrollment of all 210 planned subjects by the fourth calendar quarter of 2022, with initial topline data available as early as the first calendar quarter of 2023. The company noted that interest in the novel mechanism of action and positive interim data have helped bolster enrollment.

08:54 EDT Echo Lake criticizes independent board members of U.S. Global Investors - Ephraim Fields of Echo Lake Capital issued a letter to the independent Board of Directors of U.S. Global Investors. Mr. Fields believes the company's common stock is severely undervalued and provided several suggestions he believes can be quickly implemented that would create significant and immediate long-term shareholder value. Mr. Fields believes the company has an actual enterprise value of approximately $25 million which he believes is too low for a highly profitable company with $4 billion of AUM, a valuable ETF business and a very healthy balance sheet. The letter read, in part, " Many U.S. Global Investors investors believe the company is overcapitalized, vastly undervalued and has significant non-core assets that should be monetized. Based on our calculations, GROW's stock is trading at a mere 2.0x LTM operating income, which seems quite low for a highly profitable company with $4 billion of AUM, a valuable ETF business, and a very healthy balance sheet...We believe GROW's depressed valuation indicates the investment community has lost faith in your ability and/or willingness to take the steps necessary to create long-term shareholder value. Fortunately, we believe there are several initiatives you could easily implement that would resolve this problem and create immediate and significant long-term shareholder value. Return significant amounts of capital to shareholders through a buyback and/or special dividend. We believe GROW is overcapitalized and will have even more excess capital if the Board monetizes non-core assets as we suggest below. While the company has had a buyback in place for a very long time, a close examination reveals the buyback has barely been used and in our opinion is far too small. We can think of no better use of capital than returning it to its rightful owners, the shareholders. Monetize the HIVE convertible debenture and warrants. We believe the HIVE investment hurts GROW's valuation because it gives the investment community the mistaken impression that GROW is a cryptocurrency play. In reality, GROW generates no operating income from its HIVE investment. Furthermore, if GROW investors want to own HIVE, they can do so by purchasing HIVE stock in the open market.. there is no need for investors to get exposure to HIVE through GROW. Monetize all other assets that are not related to operating the ETF and mutual fund business. The market is not giving GROW an appropriate value for these assets and there is no strategic reason for GROW to retain these assets. Sell or obtain a prudently sized mortgage for GROW's headquarters which we believe management has stated is worth approximately $6 million. We question why this asset has remained unlevered during a period of such low interest rates and why the Company needs to own a building that it does not even fully utilize. Significantly reduce operating expenses. We believe Board and management compensation is too high and that other expenses can be dramatically reduced without harming the company's long-term prospects. We also believe the company should carefully assess its growth investments considering GROW competes against several much larger companies. Forbid related party transactions and prohibit GROW from investing in any entity in which Mr. Holmes is also invested. We find these transactions to be unnecessary and more importantly harmful to GROW shareholders as these transactions can create the perception that corporate assets are not being used in the best interests of GROW shareholders. Require Mr. Holmes to immediately relinquish all executive roles at HIVE. We believe GROW shareholders would benefit greatly if Mr. Holmes spent more time on GROW and less time on HIVE. Require Board members and senior management to personally purchase a significant number of GROW shares in the open market in order to better align their incentives with those of all shareholders. Despite our grave concerns about the Board, GROW has some very attractive assets that should be valued at much higher levels in the public market. We also believe GROW is subscale and could easily be sold for significantly more than its current enterprise value."

08:51 EDT Smith-Midland Corp awarded soundwall contract for Hampton Roads project - Smith-Midland Corporation has been awarded a new soundwall contract that expands Smith-Midland's participation on the historic Hampton Roads Bridge Tunnel Project in Hampton, VA. The $2 million contract will require nearly 1,000 precast soundwall panels of various sizes and will have a drystack stone appearance with custom starfish and frigate medallions symbolizing the ocean and military presence in the region. The panels will also utilize SoftSound, Smith-Midland's patented sound absorptive wood aggregate material, to dampen the noise coming from I-64 traffic. Delivery of the panels will begin this summer. The five-year long, $3.8B project will widen the current segments of the 1-64 HRBT corridor in Norfolk and Hampton to eight lanes and bore new twin tunnels under the James River, making this is the largest civil construction contract ever awarded by the Virginia Department of Transportation.

08:49 EDT McDonald's sees elevated inflationary pressures continuing throughout 2022

08:48 EDT Unity Bancorp board increases quarterly dividend 10% to 11c per share - Unity Bancorp, parent company of Unity Bank, announced that its Board of Directors has declared a cash dividend of 11c per common share. Such dividend is payable on June 24, 2022, to shareholders of record as of June 10, 2022. This represents an 10% increase from the 10c dividend per common share paid in the prior quarter, and a 22% increase from the 9c dividend per common share paid in June 2021.

08:48 EDT Zymeworks: Enrollment in HERIZON-BTC-01 trial for antitumor activity complete - Zymeworks announced that it has completed enrollment in its global HERIZON-BTC-01 pivotal clinical trial evaluating the antitumor activity of zanidatamab monotherapy in patients with previously treated advanced or metastatic HER2-amplified biliary tract cancers including gallbladder cancer and cholangiocarcinoma Efficacy and safety results from HERIZON-BTC-01 are expected to be announced by early 2023. "Completing enrollment in our first pivotal trial is a tremendous accomplishment for Zymeworks. I'm extremely proud of our team and our collaborators at BeiGene for their hard work in reaching this milestone ahead of expectations," said Neil Josephson, M.D., Chief Medical Officer. "Currently there are limited options for patients with advanced HER2-amplified biliary tract cancer who experience disease progression after front-line therapy. Zanidatamab has the potential to meet the urgent global clinical need for a safe and effective therapy for patients with this difficult to treat cancer." Biliary tract cancers, including gallbladder cancer and cholangiocarcinoma, account for approximately 3% of all adult cancers and is often associated with a poor prognosis1. Globally, more than 210,000 people are diagnosed with BTC every year2 and most patients with BTC are diagnosed with tumors that cannot be removed surgically. The human epidermal growth factor receptor 2 is a well-described target for anti-cancer therapy. About 5% to 19% of patients with BTC have tumors that express HER23, suggesting that these patients may have the potential to benefit from HER2-targeted therapy. Currently no HER2-targeted therapy has been approved for the treatment of BTC.

08:46 EDT Alimera Sciences announces abstracts on ILUVIEN at ARVO conference - Alimera Sciences announced that ILUVIEN will be highlighted in various scientific abstracts at the annual Association for Research in Vision and Ophthalmology, ARVO, conference being held in Denver, Colorado from May 1-4 and virtually May 11-12, 2022. Key ILUVIEN Abstracts: Presentation: "Three Year Outcomes from the PALADIN Phase IV Study: Predictive Value of Prior Steroid Challenge and Intraocular Pressure Outcomes." Posters: "Three Year Outcomes from the PALADIN Phase IV Study: Distribution of Intraocular Pressure Outcomes by Patient Subgroup." "Safety and effectiveness of the fluocinolone acetonide intravitreal implant: Final study results from the European IRISS registry study."

08:45 EDT Caterpillar says sales rose in all three primary segments in Q1 - Says sales would have been stronger if not for supply chain constraints. Says continues to experience constraints with semiconductors and other components. Expects to gain operating leverage when supply constraints ease. Seeing strong end-user demand across segments. Seeing increased quotes for autonomous solutions. Says Q1 sales in China half the level of prior year. Comments taken from Q1 earnings conference call.

08:43 EDT American Noble Gas commences drilling operations on exploratory well - American Noble Gas announced that the drilling rig has moved on location today and is in process of spudding the initial well and setting surface casing. This marks the commencement of exploratory drilling operations regarding AMGAS's participation in its previously announced farm-out agreement to develop its natural gas, helium and brine mineral interests in the Hugoton Field in Haskell and Finney Counties Kansas. The Hugoton Farm-out Venture has been granted a permit by the State of Kansas for its initial well in which AMGAS has acquired a 40% participation together with three other venture partners and has commenced exploration drilling operations with surface casing to be cemented within thirty-six hours and the target pay-zone formations expected to be reached with testing beginning on or about May 3rd 2022. The initial exploratory well will evaluate multiple members of the targeted formation applying normal and unconventional evaluation methods. Such methods will include appropriate gas detection, electric and radioactive logging in order for the Hugoton Farm-out Venture to determine the commercial viability of the natural gas and helium reserves in place. While utilizing unconventional methods, our exploratory well may reveal important data on previously untapped gas in-place reserves of natural gas and helium gas which may indicate the discovery of substantial new reserves within the Hugoton Gas Field. AMGAS and its Venture partners will perform all testing of the target zones it considers necessary to determine the existence of natural gas and helium reserves in-place including the commercial viability of producing both natural gas and helium in the exploratory well. The exploratory well will be completed for production activities pending results of the relevant testing procedures and processes. The Company will apprise shareholders of its progress including the release

08:41 EDT Duck Creek Technologies holds One Duck Creek Diversity Summit - Duck Creek Technologies held its inaugural One Duck Creek Diversity Summit, April 26-28, 2022, in Boston, Massachusetts, to bring company leaders together and to build inclusive and diverse learning experiences. Duck Creek CEO, Mike Jackowski, kicked off the event highlighting the company's DE&I mission and commitment to fostering a culture that cares about, learns from, and respects workplace diversity. The One Duck Creek Diversity Summit included myriad topical sessions and a volunteer event led by diversity, equity and inclusion champions. Duck Creek's DE&I Council, which hosted the event, ensures a diverse collection of people, voices, andperspectives are represented, respected, and empowered to thrive atDuck Creek. The group is comprised of volunteer representatives from all functions across the organization and across the globe. Duck Creek's DE&I Council is part think-tank and part action-focused - a group committed to advancing an inclusive culture and the company's DE&I mission. Council members, Employee Resource Group leads, and guests dedicated their time together to reflect on past initiatives and plan future endeavors and goals based on macro-societal, economic and workplace trends.

08:40 EDT T2 Biosystems forms Scientific Advisory Board - T2 Biosystems announced the formation of its Scientific Advisory Board, comprising leading clinicians and researchers in the areas of infectious disease, laboratory medicine, and pharmacy. The newly formed SAB will provide insights regarding T2 Biosystems' clinical utilization, product pipeline, preclinical development, clinical research, clinical data generation, and strategic guidance to advance the Company's mission. The SAB is chaired by Aparna Ahuja, M.D., Chief Medical Officer of T2 Biosystems, the inaugural meeting was held during the first quarter of 2022, and the inaugural members include: Sean Zhang: Dr. Zhang is an Associate Professor of Pathology at the Johns Hopkins University School of Medicine and the Medical Director of Medical Mycology Laboratory at the Johns Hopkins Hospital. Thomas J. Walsh: Walsh serves as the Founding Director of the Center for Innovative Therapeutics and Diagnostics , Henry Schueler Foundation Scholar, Investigator of Emerging Infectious Diseases of the Save Our Sick Kids Foundation, and Adjunct Professor of Medicine, Microbiology, and Immunology, University of Maryland School of Medicine. Denise L. Uettwiller-Geiger: Dr. Uettwiller-Geiger is a Clinical Chemist and Clinical Transformation Liaison for Mather Hospital Northwell Health, Port Jefferson, New York. James W. Snyder: Dr. Snyder is the Director of Microbiology and Infectious Diseases Molecular Diagnostic Laboratory at the University of Louisville Hospital. Michael J. Rybak: Dr. Rybak is Professor of Pharmacy, Department of Pharmacy Practice, Director, Anti-Infective Research Laboratory, Eugene Applebaum College of Pharmacy & Health Sciences, Wayne State University. George Pankey: Dr. Pankey is Director, Infectious Disease Research at the Ochsner Clinic Foundation in New Orleans and Clinical Professor of Medicine at Tulane. M. Hong Nguyen: Dr. Nguyen is Professor of Medicine and Co-Director of the Center for Healthcare Mycology at the University of Pittsburgh, as well as Director of the Transplant Infectious Diseases and Antimicrobial Management Programs at the University of Pittsburgh Medical Center. Randall T. Hayden: Dr. Hayden is Director of the Division of Clinical Pathology and Global Pathology and Director of Clinical and Molecular Microbiology in the Department of Pathology at St. Jude Children's Research Hospital.

08:38 EDT CNS Pharmaceuticals' study of Berubicin in GBM approved in Spain - CNS Pharmaceuticals has received approval from the Spanish Agency for Medicines and Health Products - AEMPS - Competent Authority and from the CElm Provincial de Sevilla Ethics Committee in Spain for the Company's potentially pivotal study of Berubicin for the treatment of recurrent glioblastoma multiforme - GBM -, one of the most aggressive types of brain cancer. Berubicin is a novel anthracycline and the first anthracycline to appear to cross the blood-brain barrier currently being evaluated in a potentially pivotal global study evaluating its efficacy and safety in the treatment of GBM. Overall Survival is the primary endpoint of the study. A pre-planned, non-binding futility analysis will be performed after approximately 30 to 50% of all planned patients have completed the primary endpoint at 6 months. The FDA recently granted CNS Pharmaceuticals Fast Track Designation for Berubicin.

08:37 EDT McDonald's 'pleased' to see strong recovery in international markets in Q1

08:36 EDT Trinity Place closes Berkley sale for $71.02M - Trinity Place Holdings announced that it, along with its joint venture partner, has closed on the sale of The Berkley, at 223 North 8th Street in Williamsburg, Brooklyn to TF Cornerstone for $71.02M. The Company purchased a 50% interest in the Property alongside Pacolet Milliken in December 2016. The net proceeds from the sale, after repayment of the property's mortgage and partner loan and settlement proceeds from the interest rate swap associated with the Property's mortgage will be used for working capital and/or new investment opportunities for the Company.

08:33 EDT PCSB Financial board increases quarterly dividend 17% to 7c per share - On April 27, 2022, the Board of Directors declared a regular quarterly cash dividend of $0.07 per share, representing a 17% increase compared to the linked quarter. The dividend is payable on or about May 27, 2022 to shareholders of record as of the close of business on May 13, 2022.

08:29 EDT LSB Industries in deal to capture over450,000 MT of carbon annually - LSB Industries announced that it entered into an agreement with Lapis Energy to develop a project to capture and permanently sequester CO2 at LSB's El Dorado, Arkansas facility. Lapis, backed by Cresta Fund Management, a Dallas-based middle-market infrastructure investment firm, will make 100% of the capital investment required for the project development. The project will commence immediately, with expected completion by 2025, subject to the approval of a Class VI permit, at which time CO2 injections will begin. This is the first carbon capture and sequestration project announced in the state of Arkansas and the third CCS project from ammonia production in the U.S.

08:26 EDT Global Blood Therapeutics releases inaugural ESG report - Global Blood Therapeutics released its inaugural environmental, social and governance, ESG, report, which highlights GBT's efforts to deliver long-term sustainable value for SCD patients and more broadly for the communities in which it serves and operates. "Since our founding, GBT has been focused on areas in which we believe we can make the largest impact and deliver the greatest value. Our business strategies, values and social purpose have been intentionally woven together, ensuring ESG is always at the core of our business. Every day, GBT employees around the world work to advance our goal to transform the lives of people living with SCD and other underserved orphan diseases - while upholding our ethics and values in all that we do," said Ted W. Love, M.D., president and chief executive officer of GBT. "We're proud of the progress we've made thus far, guided by the cultural values that are in our DNA as a company. Our first ESG report comes at a pivotal moment for SCD patients, as new medicines are becoming more broadly available but significant equity gaps remain. Our report demonstrates our progress toward advancing our ESG journey and our shared commitment to a sustainable future built through Hope, Science and Community."

08:25 EDT PPG to invest $17M to build ASC in France - PPG announced that it will invest $17M to build an aerospace application support center, or ASC, in Toulouse, France. PPG anticipates breaking ground for the new facility in the third quarter of 2022 and beginning operations in the fourth quarter of 2023. The facility will be located near aerospace customers and the Toulouse Blagnac Airport. This will be the fifth PPG ASC in the Europe, Middle East and Africa region and the second in France, in addition to the ASC in Gonfreville.

08:23 EDT Cytek Biosciences appoints Garland as CCO - Cytek Biosciences announced the appointment of Todd Garland as Chief Commercial Officer, CCO, Cytek Biosciences. Garland's appointment is effective immediately, reporting directly to Dr. Wenbin Jiang, Chairman and CEO of Cytek Biosciences.

08:22 EDT Cellectis publishes two articles on UCART123 - Cellectis announced the publication of two manuscripts in Nature Communications on its product candidate UCART123, currently being evaluated in the Phase 1 dose-escalation trial AMELI-01 in patients with relapsed or refractory acute myeloid leukemia. These preclinical data demonstrate the robust in vitro and in vivo activity of UCART123 and provide pre-clinical proof of concept for an allogenic CART cell approach to tackle AML. Allogeneic TCRab Deficient CAR T-cells Targeting CD123 in Acute Myeloid Leukemia: This preclinical study demonstrated that Cellectis' product candidate UCART123 effectively eliminates AML cells in vitro and in vivo with improvements in overall survival and minimal impact against normal hematopoietic progenitors. Preclinical results showed that: UCART123 demonstrates cytotoxic activity against primary AML samples with minimum toxicity against normal hematopoietic progenitor cells; UCART123 targets AML cells in vivo and results in improved overall survival in patient-derived xenografts models; UCART123 selectively clears primary AML cells, without affecting hematopoiesis, in a competitive humanized mouse model harboring primary AML and normal bone marrow cells; and Targeting CD123 in Blastic Plasmacytoid Dendritic Cell Neoplasm using Allogeneic Anti-CD123 CAR T Cells. Targeting CD123 in Blastic Plasmacytoid Dendritic Cell Neoplasm using Allogeneic Anti-CD123 CAR T Cells: This preclinical study demonstrated the antitumor activity of UCART123 in preclinical models of blastic plasmacytoid dendritic cell neoplasm. Preclinical results showed that: UCART123 cells result in specific killing of BPDCN primary samples in vitro and in xenograft experiments in vivo; Cytokine production levels in mice correlate with tumor burden at the time of UCART123 administration; and Tumor relapse was observed upon loss of CD123, through diverse genetic mechanism, in one of the PDX models

08:20 EDT Procept announces new healthcare coverage decisions made on Aquablation therapy - PROCEPT BioRobotics announced that Aetna US Healthcare published an update to their Benign Prostatic Hyperplasia, BPH, Clinical Policy Bulletin that provides a positive coverage position expanding access to Aquablation therapy for the treatment of their members with BPH. The revised policy is effective April 26, 2022. In addition, Independence Blue Cross Blue Shield, the leading health insurance company in southeastern Pennsylvania, and a licensee of the Blue Cross Blue Shield Association, updated its policy for surgical treatments for BPH to include Aquablation therapy as medically necessary when certain criteria are met. Independence Blue Cross covers approximately 4 million covered lives and the policy took effect April 25, 2022. "We are pleased to see these large commercial plans recognize the clinical outcomes of the recently published five-year data from the WATER study," said Reza Zadno, President and CEO. "We have made considerable progress in the last 18 months, now having five of the seven largest U.S. commercial payors establishing positive coverage policies for Aquablation therapy to provide men suffering from BPH a surgical treatment option that is clinically proven to consistently remove prostate tissue independent of prostate size, anatomy, or surgeon experience, with low risk of irreversible outcomes."

08:20 EDT Chipotle to award 2,000 medical professionals with free Chipotle for a year - Chipotle Mexican Grill announced it is recognizing healthcare heroes by awarding 2,000 medical professionals with free Chipotle for a year, equivalent to more than $1 million total in free Chipotle. This gesture will mark the most "free Chipotle for a year" awards given out at one time in the brand's history. Through May 6, National Nurses Day, fans can tag a healthcare hero that has made a positive impact on their life or their community and leave a comment about their incredible efforts in the following posts on Chipotle's Facebook, Instagram, and Twitter channels: https://fb.watch/cGeQO6b0EF/, https://www.instagram.com/p/Cc5MQY8ljI9/, https://twitter.com/ChipotleTweets/status/1519646153972674560. Starting the week of May 9, Chipotle will randomly select 2,000 medical professionals tagged in fans' comments to receive free Chipotle for a year. Chosen healthcare heroes will be notified through direct messages.

08:18 EDT Immutep to announce new TACTI-002 data in presentation at ASCO 2022 meeting - Immutep announces new interim data from first line non-small cell lung cancer patients of the Phase II TACTI-002 trial has been selected for a prestigious Oral Presentation at the American Society of Clinical Oncology's, ASCO, 2022 Annual Meeting. In addition, the Phase IIb TACTI-003 trial design will be presented in a Trial-in-Progress Poster Presentation. TACTI-002 Oral Presentation: Title: "A Phase II study in 1st line metastatic non-small cell lung carcinoma investigating eftilagimod alpha and pembrolizumab: updated results from a PD-L1 unselected population." TACTI-003 Poster Presentation: Title: "TACTI-003: A randomized Phase IIb study of eftilagimod alpha and pembrolizumab as first-line treatment of patients with recurrent or metastatic head and neck squamous-cell carcinoma."

08:16 EDT Enphase Energy expands battery storage in Michigan - Enphase Energy announced that installers of Enphase products in Michigan have seen growing deployments of Enphase Energy Systems powered by IQ Microinverters and IQ Batteries. Residential battery installations in Michigan are growing steadily year-over-year with forecasts estimating deployments will more than double by the end of 2026, according to the most recent U.S. Energy Storage Monitor report from the Energy Storage Association and Wood Mackenzie.

08:14 EDT Osisko announces proxy firms recommend shareholders vote for proposed items - Osisko Gold Royalties will hold its 2022 annual meeting of shareholders on Thursday, May 12, 2022. The company said, "We are pleased to announce that the two leading independent proxy advisory firms that provide voting recommendations to institutional investors, Institutional Shareholder Services Inc. and Glass Lewis & Co., have each recommended shareholders to vote FOR in respect of all resolutions to be put forth at the Meeting."

08:13 EDT MSCI, MarketAxess announces strategic collaboration - MSCI (MSCI) and MarketAxess (MKTX) have agreed to enter into a strategic collaboration to "create innovative portfolio analytics solutions and co-branded fixed income indexes incorporating MarketAxess liquidity data," the company said. MSCI plans to integrate MarketAxess' AI-powered pricing and liquidity measures, including Relative Liquidity Score and Tradability, into MSCI's portfolio construction analytics tools and its fixed income indexes. MarketAxess plans to leverage MSCI's ESG ratings to identify and create more liquid and sustainable fixed income portfolios for its global institutional clients. Henry Fernandez, Chairman and CEO of MSCI, said: "MSCI is committed to expanding and enhancing our fixed income solutions to reflect the increasingly complex needs of the institutional investment community. As bond markets continue to evolve beyond over-the-counter trading coupled with compressed management fees, investors seek to effectively analyze and index fixed income securities. MSCI's strategic collaboration with MarketAxess will empower investors with portfolio analytics and index products, in addition to offering them tools and robust datasets in growing areas of interest, namely ESG." The strategic collaboration is subject to the execution of definitive agreements.

08:11 EDT Lakeland Bancorp increases quarterly dividend 7% to 14.5c per share - On April 26, 2022, the Company declared a quarterly cash dividend of $0.145 per share to be paid on May 18, 2022, to shareholders of record as of May 9, 2022. This represents an annualized 7% increase in the Company's dividend. Thomas Shara, Lakeland Bancorp's President and CEO commented, "Aside from the 1st Constitution merger related items, our quarterly results were solid as our asset quality remained stellar, net interest margin expanded, organic loan growth continued, and pre-provision net revenue increased. Considering our financial strength, the Board authorized an annualized 7% increase in our quarterly cash dividend per share."

08:08 EDT Newcrest reports no significant assay results from Cornerstone's Miocene Project - Cornerstone Capital Resources announces that Newcrest Mining, which has a farm-in agreement with Cornerstone for the Miocene gold-copper project in Chile, reported the following in its quarterly exploration report out: "Drilling was conducted across Newcrest's Chilean exploration project portfolio with 2,216m drilling completed during the quarter at Mioceno and Esparta. Complete assays were received, with no significant results and interpretation of the data is ongoing." Cornerstone has not yet received the report containing Newcrest's analysis of the data nor its intentions with respect to the Miocene farm-in agreement going forward but will inform the market in due course once that has been received.

08:06 EDT ArcBest expands share repurchase program to $75M - ArcBest has reauthorized its Common Stock repurchase program and increased the total amount available to $75M.

08:04 EDT MasterCard reports Q1 switched transactions up 22%

08:03 EDT MasterCard off to a strong start in 2022, says CEO Michael Miebach - "Russia's invasion of Ukraine marked a somber start to 2022, as war returned to Europe for the first time in decades," said Michael Miebach, Mastercard CEO. "Even in the context of this challenging geopolitical environment, we're off to a strong start in 2022 with robust revenue and earnings growth as cross border volumes grew 53% versus a year ago on a local currency basis. As of March, cross-border travel is above 2019 levels for the first time since the pandemic began, and ahead of our expectations. We continue to make good progress against our strategic priorities, deepening relationships with key issuers and co-brand partners across the globe. We're seeing strong traction in consumer and small business payments, Mastercard Installments and our work across the digital asset space. This complements the continued growth of acceptance and the expansion of our services capabilities through our acquisition of Dynamic Yield."

08:03 EDT MasterCard reports Q1 gross dollar volume up 17%, purchase volume up 21%

07:57 EDT American Resources secures worldwide rights to patent for battery-grade metals - American Resources Corporation announced that it has secured the exclusive worldwide rights for a new provisional patent filed by the Company's technology and research partner, Purdue University, for the isolation and purification of battery-grade materials using multi-mode chromatography for all feedstocks. The provisional patent was filed on March 25th, 2022 by the Purdue Research Foundation for the purpose of establishing and protecting the Company's "versatile multi-dimension and multi-mode chromatography methods for producing high-purity lithium, cobalt, nickel, and manganese salts with high yields from all feedstocks including end-of-life batteries."

07:53 EDT SmileDirectClub completes $255M secured debt facility - SmileDirectClub announced that SDC U.S. SmilePay SPV, a wholly-owned special purpose subsidiary of the Company, completed a new $255 million secured debt facility, strengthening the Company's liquidity and providing greater flexibility to fuel its continued operations and future growth plans. The Company entered into a Loan Agreement by and among SPV, as borrower, SmileDirectClub, LLC as the seller and servicer, the lenders from time to time party thereto, and HPS Investment Partners, LLC, as administrative agent and collateral agent, providing a 42-month secured delayed-draw term loan facility to SPV in an aggregate maximum principal amount of up to $255 million. On April 27, 2022, $65 million was outstanding under the new Loan Agreement. Subject to certain exceptions, the Loan Agreement is secured by first-priority security interests in SPV's assets, which consist of certain receivables, cash, intellectual property and related assets. SPV's obligations under the Loan Agreement are guaranteed on a limited basis by SmileDirectClub, LLC and SDC Financial.

07:52 EDT Edesa enrolling patients for Phase 2b study of EB01 faster than expected - Edesa Biotech announced that patient recruitment for a Phase 2b clinical study evaluating the company's drug candidate, designated EB01, as a monotherapy for chronic allergic contact dermatitis, ACD, has been enrolling ahead of schedule. Based on the current pace of recruitment, which had previously been impacted by pandemic-related shutdowns, the company anticipates completing enrollment of all 210 planned subjects by the fourth calendar quarter of 2022, with initial topline data available as early as the first calendar quarter of 2023. The company noted that interest in the novel mechanism of action and positive interim data have helped bolster enrollment. "As patients return to work and re-enter social circles, there's both an increase in potential exposure to the causal allergens and a greater desire to treat the inflammation," said Par Nijhawan, MD, Chief Executive Officer of Edesa. "EB01 is being developed as a safe and effective alternative to steroids. This is especially important for ACD patients with chronic lesions, which are often on the hands and face and problematic to treat long-term with steroids." The double-blind, placebo-controlled confirmatory study is evaluating the safety and efficacy of 2.0% EB01 cream in approximately 170 evaluable subjects in total. In addition to the primary cohort, the company has included an exploratory, dose-ranging component of the study, which will separately evaluate lower-strength concentrations of EB01 in an additional 40 subjects.

07:51 EDT Zai Lab, Turning Point announce topline analysis from Phase 1/2 TRIDENT-1 study - Zai Lab and Turning Point Therapeutics announced topline data for repotrectinib within the China region from the previously disclosed Phase 1/2 TRIDENT-1 study dataset. The primary objective of the TRIDENT-1 study is to determine the cORR based on BICR as assessed by RECIST 1.1. DOR is a key secondary objective of the study. The dataset utilizes a February 11, 2022 data cutoff date. The global safety analysis included 380 treated patients from the pooled Phase 1 and Phase 2 portions of TRIDENT-1 across all cohorts. The global efficacy analyses included pooled patients from Phase 1 across all dose levels with an identified ROS1 fusion by next generation sequencing at baseline and Phase 2 patients. All patients received at least one dose of repotrectinib with at least four months of follow-up, and the majority of responders had at least six months of DOR follow-up. In TKI-naive patients, in 71 total patients, there was a cORR of 79% across the global trial. Ten of 11 patients responded within China for a cORR of 91% and DOR ranged from 3.6+ to 7.5+ months with a median duration of follow-up of 3.7 months. In patients previously treated with 1 TKI and platinum-based chemotherapy, in 26 total patients, there was a cORR of 42% across the global trial. Two of 3 patients responded within China for a cORR of 67% and DOR ranged from 3.6+ to 3.7+ months with a median duration of follow-up of 3.7 months. In patients previously treated with two TKIs without prior chemotherapy, in 18 total patients, there was a cORR of 28% across the global trial. Two of 4 patients responded within China for a cORR of 50% and DOR ranged from 1.9+ to 3.4+ months with a median duration of follow-up of 2.6 months. In patients previously treated with 1 TKI without prior chemotherapy, in 56 total patients, there was a cORR of 36% across the global trial. Four of 11 patients responded within China for a cORR of 36% and DOR ranged from 2.0+ to 3.7+ months with a median duration of follow-up of 3.1 months. Repotrectinib was generally well tolerated in a total of 380 patients treated globally with a safety and tolerability profile that was consistent with previously reported findings. The most commonly reported treatment emergent adverse event remained dizziness, of which 76% of patients who reported dizziness had a maximum severity of grade 1. The safety profile was comparable among the 287 patients who were treated at the Phase 2 dose. The TRIDENT-1 study continues to enroll patients globally across the study. As previously guided, Turning Point Therapeutics anticipates discussing the topline BICR data for the ROS1-positive advanced NSCLC cohorts with the U.S. Food and Drug Administration at a pre-NDA meeting this quarter. Turning Point Therapeutics plans to present detailed study results, including intracranial activity, from the ROS1-positive advanced NSCLC cohorts of the TRIDENT-1 study, at a medical conference in the second half of 2022. Zai Lab plans to complete enrollment in the phase 1/2 registrational TRIDENT-1 study and discuss the regulatory pathway with the National Medical Products Administration at a pre-NDA meeting in the fourth quarter of 2022.

07:46 EDT PyroGenesis announces commissioning of DROSRITE technology - PyroGenesis Canada is pleased to confirm that, further to the press releases dated April 20th, 2022, and April 25th, 2022, the Company's DROSRITE technology has once again been successfully commissioned, this time at an existing North American automobile parts manufacturer client and completed Site Acceptance Testing. The name of the Client remains anonymous for confidentiality reasons. This system, which was part of a two-system order, originally intended for delivery to an Asian client and discussed in a previous press release, was subsequently fully paid for. Due to significant delays in the Asian client's ability to expand their facility, PyroGenesis sold the two units to an existing Client who assumed the contract. The contract was for two DROSRITE systems, each with a capacity of 5,000 tons/year. Both systems were completed and delivered to the Client's facility. PyroGenesis' Client now has three DROSRITE systems in operation. The fourth system will be commissioned upon an expected increase in production demand for the Client's offerings. Although these systems have been installed at the Client's facility for some time, the Client has chosen to commission them based on a predetermined production schedule.

07:44 EDT Galmed's Aramchol shows fibrosis improvement in open-label study - Galmed announced interim results from the Open-Label Part of the ARMOR study showing fibrosis improvement with Aramchol using multimodality histological assessment. The Open-Label Part of the ARMOR study was designed to explore the kinetics of histological outcome measures as a function of treatment duration. This part was also used to further assess different methodologies that may support and improve fibrosis scoring, in preparation for the registrational double-blind, placebo-controlled part of the study. Results of post baseline biopsies performed either at 24 weeks or at 48 weeks from 46 subjects with NASH and F1-3 that received Aramchol support the anti-fibrotic effect of Aramchol and reinforce the favorable safety profile of Aramchol. Treatment with Aramchol 300mg BID resulted in a high rate of subjects with fibrosis improvement across the three pathology reading methods. Both paired and AI evaluations identified more subjects with fibrosis improvement, indicating greater sensitivity to detect change. For all methods, a treatment effect was larger at 48 compared to 24 weeks.

07:43 EDT Marimed completes acquisition of Kind Therapeutics U.S.A. - MariMed announced it completed the acquisition of Kind Therapeutics U.S.A., a vertically integrated cannabis business in Maryland. The Maryland Medical Cannabis Commission approved the transfer to MariMed at their April 13th meeting and the closing took place April 27, 2022. MariMed was instrumental in the development of the Kind operations from its inception in 2017. The Company owns, and had developed, a 180,000 square foot cannabis cultivation and production facility in Hagerstown and is developing a 6,000 square foot dispensary in Anne Arundel County, both of which were leased to Kind. MariMed intends to expand all of aspects of the Kind business including adding 40,000 square feet of cultivation canopy, a state-of-the-art GMP kitchen, and new and innovative cannabis brands and products to be distributed throughout the robust Maryland cannabis marketplace. With the closing of this transaction MariMed will report 100% of Kind's revenue and profits in its financials. The transaction demonstrates progress and the Company's commitment to its strategic growth plan.

07:41 EDT Turning Point Therapeutics, Zai Lab announce data for repotrectinib in China - Turning Point Therapeutics (TPTX) and Zai Lab (ZLAB) announced topline data for repotrectinib within the China region from the previously disclosed Phase 1/2 TRIDENT-1 study dataset. The primary objective of the TRIDENT-1 study is to determine the cORR based on BICR as assessed by RECIST 1.1. DOR is a key secondary objective of the study. The dataset utilizes a February 11, 2022 data cutoff date. Topline Efficacy Analyses by BICR: In TKI-naive patients, in 71 total patients, there was a cORR of 79% across the global trial. Ten of 11 patients responded within China for a cORR of 91% and DOR ranged from 3.6+ to 7.5+ months with a median duration of follow-up of 3.7 months. In patients previously treated with 1 TKI and platinum-based chemotherapy, in 26 total patients, there was a cORR of 42% across the global trial. Two of 3 patients responded within China for a cORR of 67% and DOR ranged from 3.6+ to 3.7+ months with a median duration of follow-up of 3.7 months. In patients previously treated with two TKIs without prior chemotherapy, in 18 total patients, there was a cORR of 28% across the global trial. Two of 4 patients responded within China for a cORR of 50% and DOR ranged from 1.9+ to 3.4+ months with a median duration of follow-up of 2.6 months. In patients previously treated with 1 TKI without prior chemotherapy, in 56 total patients, there was a cORR of 36% across the global trial. Four of 11 patients responded within China for a cORR of 36% and DOR ranged from 2.0+ to 3.7+ months with a median duration of follow-up of 3.1 months. Global TRIDENT-1 Topline Safety Analyses: Repotrectinib was generally well tolerated in a total of 380 patients treated globally with a safety and tolerability profile that was consistent with previously reported findings. The most commonly reported treatment emergent adverse event remained dizziness, of which 76% of patients who reported dizziness had a maximum severity of grade 1. Turning Point Therapeutics plans to present detailed study results, including intracranial activity, from the ROS1-positive advanced NSCLC cohorts of the TRIDENT-1 study, at a medical conference in the second half of 2022. Zai Lab plans to complete enrollment in the phase 1/2 registrational TRIDENT-1 study and discuss the regulatory pathway with the National Medical Products Administration at a pre-NDA meeting in the fourth quarter of 2022.

07:41 EDT Huazhu Group: RevPAR recovery for Legacy-Huazhu business interrupted by COVID - Huazhu Group announced preliminary results for hotel operations in the first quarter ended March 31, 2022. COVID-19 update For our Legacy-Huazhu business, RevPAR recovery in the first two months of 2022 was on track. Nevertheless, such recovery was significantly interrupted by the large-scale outbreak of the Omicron variant in over 30 provinces in China since early-March 2022. Many cities, such as Shanghai and Jilin, have been subject to lockdown since then, which resulted in a sharp decline of both business and leisure traveling activities. However, such outbreak led to a rise in demand for hotels to serve the quarantine needs of infected persons or those in close contact with infected persons, as well as the accommodation needs of medical teams and delivery riders. As the Omicron variant is highly infectious, there are still uncertainties in terms of the impact on our Legacy-Huazhu business in the near-term. To mitigate risks, we are now implementing several costs and cash flow management measures. Steigenberger Hotels AG and its subsidiaries have been experiencing continuous RevPAR recovery since Germany unfolded its opening-up plan in mid-February 2022. RevPAR in March 2022 recovered to 65% of the 2019 level, as compared to only 47% of the 2019 level in January 2022. However, since RevPAR recovery is still at an early stage, a comprehensive cash flow improvement program remains critical. Therefore, DH will continuously focus on efficiency improvements, negotiation of further lease waivers, and personnel cost optimization.

07:40 EDT Virios Therapeutics completes enrollment in FORTRESS trial - Virios Therapeutics announced it has completed enrollment in its Phase 2b FORTRESS study, which is a randomized, double-blind evaluation of IMC-1 in patients with fibromyalgia.

07:32 EDT Domino's Pizza reports Q1 U.S. same store sales decline of 3.6% - Reports Q1 International same store sales growth (excluding foreign currency impact) of 1.2%; Global net store growth of 213. Global retail sales growth (excluding foreign currency impact) of 3.6%

07:29 EDT Baxter says Novum IQ LVP 510(k) review placed on hold - On March 21, as shared in a prior Form 8-K, Baxter submitted responses to FDA's additional information requests for the company's new Novum IQ Large Volume Pump, or LVP, and related Dose IQ Safety Software. On April 22, Baxter received an additional information request from FDA that identified an issue, the adequate resolution of which is required to obtain FDA clearance of the Novum IQ LVP. As a result, the 510(k) review has been placed on hold so that Baxter can respond accordingly. "Baxter currently expects to respond to FDA's additional information request within the calendar year. The company continues to expect submission of responses to FDA on the filing of the Novum IQ Syringe Pump in the second quarter of 2022," the company stated. "We are committed to responding to the FDA's requests, and to bringing the benefits of the Novum IQ infusion platform to patients and caregivers in the U.S. and beyond," said Baxter CEO Jose Almeida.

07:27 EDT ATI Physical Therapy names Sharon Vitti as CEO - ATI Physical Therapy announced the appointment of Sharon Vitti as CEO. Vitti will lead ATI in executing its vision of providing access to the highest-quality musculoskeletal care and patient experience while driving creative revenue models, including the adoption of value-based care and B2B offerings in physical therapy. She joins ATI after serving as president of MinuteClinic.

07:26 EDT Abbott presents new results from study of FreeStyle Libre system - Abbott announced results from a new meta-analysis of 75 real-world, observational studies demonstrating that its FreeStyle Libre system provides significant reductions in glycated hemoglobin that are sustained up to 24 months in adults with both type 1 and type 2 diabetes.1 People with type 2 diabetes who use insulin are often restricted when it comes to access to continuous glucose monitoring, but both clinical trials and real-world studies demonstrate significant improvement of glycemic control. The results were presented at the Advanced Technologies & Treatments for Diabetes Congress, April 27-30, 2022, in Barcelona. After three months of using the FreeStyle Libre system, HbA1c levels were reduced by 0.53% in adults with type 1 diabetes (from 8.20% to 7.67%) and 0.45% in adults with type 2 diabetes (from 8.17% to 7.72%). These are clinically significant reductions of average glucose levels towards the internationally recommended HbA1c goal of 7% for adults with diabetes. Reductions were sustained for up to 24 months in those with type 1 diabetes and up to 12 months in those with type 2 diabetes, reflecting the duration of the studies available for analysis. Reductions in HbA1c over time followed a similar pattern for people with type 1 and type 2 diabetes, demonstrating that, in a real-world setting, people with type 2 diabetes who use insulin benefit from FreeStyle Libre system in a similar way as people with type 1 diabetes.

07:22 EDT Wellbeing Digital's IRP Health approved as part of CPCoE - Wellbeing Digital Sciences is pleased to announce that its subsidiary, IRP Health, has been approved as part of the Chronic Pain Centre of Excellence for Canadian veterans. Additionally, IRP Health's clinic in Ottawa, Ontario has been approved by Veterans Affair Canada for its multidisciplinary Reactivation-branded therapy program. After meeting strict criteria, IRP Health's four Canadian locations will now be listed and recommended as part of the national network of clinics. The clinics will contribute towards the national collection of data to help further research and innovation with respect to the treatment of military veterans. The CPCoE provides national leadership for research co-designed with veterans and their families and supports the implementation of this research with a national network of clinics to help veterans and their families manage their pain and reconnect with life. IRP Health's Ottawa Clinic has been approved by VAC to begin offering the Reactivation therapy program at the location. Reactivation is a 12-week, physician-supervised, interdisciplinary pain management program that assists veterans with chronic musculoskeletal injuries and pain. It aims to help veterans return to behaviours that are consistent with being well, rather than behaviours that are consistent with suffering. The goals of Reactivation are to decrease distressing symptoms, increase engagement in the community and increase the ability to complete daily tasks and also strives to reduce patient disability in both the short and long term, while giving veterans better control and understanding of their pain and health challenges. The therapy program combines psychiatry, psychology, occupational therapy, physiotherapy, kinesiology, and dietetics to provide an interdisciplinary approach and a cutting-edge treatment.

07:21 EDT Spok ends strategic alternatives review process, no actionable options for sale - Spok has concluded the strategic alternatives review process it publicly commenced on September 3 . At this time, Spok has no actionable options for a sale of the Company and the Board has determined it is in the best interests of all shareholders for Spok to focus on executing its strategic plan as a standalone company. Since initiating the strategic review, the Board, along with its financial and legal advisors, conducted an exceptionally thorough process and reached out to and engaged with a wide range of strategic and financial parties. Spok's Board is fully committed to maximizing value for all shareholders.

07:20 EDT Gravity announces filing of annual report on Form 20-F - GRAVITY Co., announced that the Company filed its annual report on Form 20-F for the fiscal year ended December 31, 2021 with the Securities and Exchange Commission on April 28, 2022. The shareholders and ADS holders of Gravity may receive a hard copy of the annual report, which contains its audited consolidated financial statements, free of charge upon request. Requests should be directed to IR Unit, Gravity Co., Ltd., 15F, 396 World Cup buk-ro, Mapo-gu, Seoul 03925, South Korea. In the annual report on Form 20-F, the consolidated revenue is KRW 413,938 million, the operating profit is KRW 96,719 million, and the net profit attributable to parent company is KRW 65,947 million for the fiscal year ended December 31, 2021.

07:17 EDT Enact initiates dividend program, announces inaugural quarterly dividend - Enact Holdings announced that its Board of Directors has approved the initiation of a dividend program under which the Company intends to pay a quarterly cash dividend. The inaugural quarterly dividend for the second quarter of 2022 will be 14c per share, payable on May 26, 2022 to common shareholders of record on May 9, 2022. Rohit Gupta, Enact's President and CEO stated, "The Board's decision to initiate a dividend program reflects our confidence in Enact's operating performance, as well as our commitment to drive shareholder value by returning capital to shareholders while maintaining a strong balance sheet to support the growth of our business. Going forward, we believe we are well positioned to return capital to shareholders while investing in our growth."

07:16 EDT Mallard Acquisition announces liquidation - Mallard Acquisition announced that, due to its inability to consummate an initial business combination within the time period required by its Amended and Restated Certificate of Incorporation, the Company intends to dissolve and liquidate in accordance with the provisions of its Amended and Restated Certificate of Incorporation and will redeem all of the outstanding shares of common stock that were included in the units issued in its initial public offering, at a per-share redemption price of approximately $10.10. As of the close of business on April 29, 2022, the Public Shares will be deemed cancelled and will represent only the right to receive the redemption amount. In order to provide for the disbursement of funds from the trust account, the Company has instructed the trustee of the trust account to take all necessary actions to immediately liquidate the trust account. The proceeds of the trust account will be held in a non-interest bearing account while awaiting disbursement to the holders of the Public Shares. Record holders may redeem their shares for their pro rata portion of the proceeds of the trust account by delivering their Public Shares to Continental Stock Transfer & Trust Company, the Company's transfer agent. Beneficial owners of Public Shares held in "street name," however, will not need to take any action in order to receive the redemption amount. The redemption of the Public Shares is expected to be completed within ten business days after April 29, 2022. The Company's initial stockholders have waived their redemption rights with respect to its outstanding common stock issued prior to the Company's initial public offering. There will be no redemption rights or liquidating distributions with respect to the Company's warrants, which will expire worthless. The Company also announced that it received a notice from the Listing Qualifications Department of The Nasdaq Stock Market stating that the Company is not in compliance with Nasdaq Listing Rule 5250(c)(1) because the Company failed to timely file its Annual Report on Form 10-K for the period ended December 31, 2021 with the Securities and Exchange Commission. The Notice has no immediate effect on the listing or trading of the Company's securities on the Nasdaq Capital Market. The Company intends to file its Form 10-K with the SEC as soon as practicable. However, the Company plans to liquidate, and its securities will not continue to be listed on Nasdaq subsequent to such liquidation.

07:03 EDT McDonald's reports Q1 systemwide sales up 10% - International Operated Markets segment increased 20.4%. International Developmental Licensed Markets segment increased 14.7%

07:01 EDT Southwest sees FY22 ASMs down 4% - Sees FY22 fuel cost per gallon $2.75-$2.85. Sees FY22 CASM up 12%-16%. Sees FY22 effective tax rate 24%-26%.

06:40 EDT Travel + Leisure board approves $500M increase to share repurchase plan

06:34 EDT PulteGroup reports Q1 net new orders down 19% - Reports Q1: "Closings of 6,039 Homes, consistent with prior year; Average Sales Price increased 18% to $508,000; Net New Orders lower by 19% to 7,971 homes; Net New Order Value increased 2% to $4.7B; Unit Backlog increased 5% to 19,935 homes with a value of $11.5B."

06:26 EDT Gravity: Ragnarok Labyrinth NFT exceeds over 1M downloads in Southeast Asia - Gravity announced that Ragnarok Labyrinth NFT re-opened on April 27, has exceeded over 1M downloads in Southeast Asia. Ragnarok Labyrinth NFT is the first NFT title using Ragnarok IP cooperated with ONBUFF Inc., a blockchain platform company, and the game applies P2E system and NFT to The Labyrinth of Ragnarok, a mobile Time Effective MMOPRG game. Over 1M downloads have been reached on the first day of its re-opening on April 27, and stable services for game play with improving a large scale of servers have been successfully provided to users. The game ranked as the second and the third in top grossing of Apple App Store in Thailand and the Philippines, respectively, and also ranked as the first in top new free games of Google Play in the Philippines. On top of the high-rankings, the popularity of Ragnarok IP in Southeast Asia has been proved by breaking the existing record of maximum number of concurrent users in 3 hours on its re-opening day.

06:15 EDT Hersha Hospitality to sell non-core Urban Select Service properties for $505M - Hersha Hospitality Trust announced that it has entered into a definitive agreement to sell seven of its non-core Urban Select Service properties outside of New York for gross proceeds of $505M, or approximately $360,000 per key. Jay Shah, Hersha's CEO, stated, "We're pleased to have reached an agreement that supports our long-term strategic objectives and delivers immediate shareholder value. With the sale of these non-core properties, we are able to continue our transformation by deepening our focus on our luxury & lifestyle and New York portfolios - both demonstrating resiliency coming out of the pandemic. Our resort markets and lifestyle properties continue to outperform - as reflected in our first quarter financial results announced yesterday - and our purpose-built New York City cluster, coupled with our unique operating model, positions us for strong performances across the recovery." Hersha intends to use the proceeds from the sale of the USS Portfolio to provide immediate liquidity for a significant net debt reduction of approximately $460 - $480 million. In addition to approximately $390 - $410 million of corporate debt, the company expects to reduce mortgage debt associated with the USS Portfolio by approximately $75 million, resulting in a pro forma consolidated leverage ratio of 4.9x-5.1x.1 The company also expects to recast its existing credit facility, which would eliminate all corporate-level debt maturities through 2024. Following completion of the transaction, Hersha will own 26 hotels in six key destination markets across the U.S. On a pro forma basis, the remaining portfolio's Total RevPAR based on 2019 actual performance would have increased from $206 to $219, total ADR would have increased from $247 to $262, and EBITDA per Key would have increased from approximately $32,000 to $33,000. The transaction is expected to close in the third quarter of 2022, subject to customary closing conditions.

06:10 EDT Overstock.com reports Q1 active customers 7.4M, down 26% y/y - In Q1: Last Twelve Months net revenue per active customer of $356, an increase of 26% year over year. Orders delivered of 2.4 million, a decrease of 33% year over year. Average order value of $221, an increase of 21% year over year. Orders per active customer, measured as LTM orders divided by active customers, of 1.67, an increase of approximately 1% year over year. Orders placed on a mobile device were 50% of gross merchandise sales.

06:10 EDT AstraZeneca's Ultomiris approved in U.S. for adults with gMG - The company states: "Ultomiris has been approved in the US for the treatment of adult patients with generalised myasthenia gravis, or gMG, who are anti-acetylcholine receptor (AChR) antibody-positive, which represents 80% of people living with the disease. The approval by the Food and Drug Administration (FDA) was based on positive results from the CHAMPION-MG Phase III trial, in which Ultomiris was superior to placebo in the primary endpoint of change from baseline in the Myasthenia Gravis-Activities of Daily Living Profile (MG-ADL) total score at Week 26, a patient-reported scale that assesses patients' abilities to perform daily activities. This FDA action marks the first and only approval for a long-acting C5 complement inhibitor for the treatment of gMG." Reference Link

06:07 EDT Judge rules in Musk's favor in SolarCity takeover lawsuit - On Wednesday, Vice Chancellor Joseph Slights III ruled in Elon Musk's favor in a lawsuit over SolarCity's takeover. The ruling said as follows: Tesla "announced on June 21, 2016, that it would acquire a solar energy company, SolarCity Corporation, in a stock-for-stock merger valued at the time at approximately $2.6B. Several Tesla stockholders have alleged the Acquisition, as consummated, was the product of breaches of fiduciary duty and other wrongdoing... The process employed by the Tesla Board to negotiate and ultimately recommend the Acquisition was far from perfect. Elon was more involved in the process than a conflicted fiduciary should be. And conflicts among other Tesla Board members were not completely neutralized. With that said, the Tesla Board meaningfully vetted the Acquisition, and Elon did not stand in its way. Equally if not more important, the preponderance of the evidence reveals that Tesla paid a fair price-SolarCity was, at a minimum, worth what Tesla paid for it, and the Acquisition otherwise was highly beneficial to Tesla... The Court's verdict, therefore, is for the defense."

06:05 EDT Vale board approves new 500M share buyback program - Vale said: "In continuity with the 2021 share buyback programs, our Board of Directors approved a new program of up to 500 million shares, equivalent to around 10% of the currently outstanding shares of the company, to be executed in the following 18 months and after the conclusion of the current program. Upon conclusion of the third sequential buyback, Vale's shareholders interest in the company's results will have increased by more than 22% since the approval of the first program in 2021."

05:54 EDT DigitalBridge to acquire AMP infrastructure investment management business - DigitalBridge announced that an affiliate, DigitalBridge Investments, has agreed to acquire AMP Capital's global infrastructure equity investment management business, part of its Collimate Capital subsidiary, in a transaction valued at $328M, comprising upfront payments for the management platform, fund sponsor investments, and retained performance fees, plus potential contingent payments based on certain future performance thresholds. AMP Capital's international infrastructure equity platform comprises four investment funds with $5.5B in fee-earning assets under management, including the $3.4B Global Infrastructure Fund II and $1.4B Global Infrastructure Fund I. Upon closing, 2022 projected run-rate fee related earnings from the DigitalBridge IM platform is expected to increase at the midpoint by approximately 20% over prior guidance. Upon closing, the business is expected to be immediately accretive to DigitalBridge's after-tax income per share of Class A common stock.

05:48 EDT Baidu receives first permits in China to provide driverless ride-hailing service - Baidu received the first-ever permits in China authorizing the company to provide driverless ride-hailing services to the public on open roads in Beijing. This regulatory approval marks a milestone for the autonomous ride-hailing industry in China, indicating a regulatory openness to taking a further step toward a fully driverless mobility future. With these permits issued by the head office of the Beijing High-level Automated Driving Demonstration Area, or BJHAD, ten autonomous vehicles without drivers behind the steering wheel will offer rides to passengers in a designated area of 60 square kilometers in Beijing. These licensed cars will join an existing fleet provided by Apollo Go, Baidu's autonomous ride-hailing service, in the capital city of China. Starting April 28, users will be able to hail a driverless ride using the Apollo Go mobile app in daytime from 10:00 to 16:00. Currently, Baidu has the largest autonomous driving fleet in China. In expanding its driverless vehicle services, Baidu has worked to meet the unique technical challenges of Beijing's complex traffic environment. The company plans to add 30 more such vehicles at a later stage, expanding its fleet to provide more convenient driverless services to the public.

05:31 EDT KKR to make offer to acquire Hitachi Transport System for JPY8,913 per share - KKR announced it intends to make a tender offer for the common shares of Hitachi Transport System through HTSK, an entity owned by the investment funds managed by KKR. Hitachi Transport System is a third-party logistics business in Japan. The company provides supply chain solutions for customers who outsource logistics functions such as logistics system integration, inventory and order control, logistics center operations, factory logistics, and transportation and delivery services. In connection with the tender offer, the offeror has entered into an agreement with Hitachi, the lead shareholder of HTS, under the terms of which, following a share consolidation after the tender offer, HTS will acquire Hitachi's 39.91% holding in a share buyback. Thereafter, Hitachi will reinvest by acquiring 10% of shares with voting rights in HTSK Holdings that holds shares of the offeror and KKR will hold 90% of shares with voting rights in the offeror parent. The proposed tender offer price of JPY8,913 per share and the share buyback price of JPY6,632 per share have been determined based on the negotiations among KKR, HTS, and Hitachi. This transaction will be financed predominantly from KKR's Asia IV Fund and is designed with a low-leverage capital structure for HTS's sustainable growth. KKR expects to commence the tender offer by late September 2022, subject to regulatory approvals in Japan and other jurisdictions.

05:15 EDT JinkoSolar sees Q2 total shipments 8.5-9.5 GW - Sees FY22 total shipments 35-40 GW. The company said, "The Company's business outlook is based on management's current views and estimates with respect to market conditions, production capacity, the Company's order book and the global economic environment. This outlook is subject to uncertainty on final customer demand and sale schedules. Management's views and estimates are subject to change without notice."